TW202120492A - 新穎嗒𠯤 - Google Patents
新穎嗒𠯤 Download PDFInfo
- Publication number
- TW202120492A TW202120492A TW109124572A TW109124572A TW202120492A TW 202120492 A TW202120492 A TW 202120492A TW 109124572 A TW109124572 A TW 109124572A TW 109124572 A TW109124572 A TW 109124572A TW 202120492 A TW202120492 A TW 202120492A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- formula
- lpa
- Prior art date
Links
- 150000004892 pyridazines Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 104
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 19
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 230000003176 fibrotic effect Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000003566 oxetanyl group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 60
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 abstract description 22
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 230000006806 disease prevention Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 abstract description 2
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 66
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 60
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 57
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 101000897035 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 208000029523 Interstitial Lung disease Diseases 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- -1 elixirs Substances 0.000 description 14
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 14
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 230000004761 fibrosis Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940122849 Autotaxin inhibitor Drugs 0.000 description 4
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 4
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N methyl tert-butyl ether Substances COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 208000008864 scrapie Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 3
- ULUNQYODBKLBOE-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrole Chemical compound C1=CNC(C=2NC=CC=2)=C1 ULUNQYODBKLBOE-UHFFFAOYSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010008635 Cholestasis Diseases 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010050207 Skin fibrosis Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000006887 Ullmann reaction Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- ZNOVTXRBGFNYRX-UHFFFAOYSA-N 2-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-UHFFFAOYSA-N 0.000 description 2
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- VMOBEAUQUPPPON-UHFFFAOYSA-N 3-fluoro-4-piperazin-1-ylbenzonitrile Chemical compound FC1=CC(C#N)=CC=C1N1CCNCC1 VMOBEAUQUPPPON-UHFFFAOYSA-N 0.000 description 2
- QZCALUXJSUJBPF-UHFFFAOYSA-N 4-(2,7-diazaspiro[3.5]nonan-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1N1CC2(CCNCC2)C1 QZCALUXJSUJBPF-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BRVBDVOTMCVCCE-UHFFFAOYSA-N 4-(4-acetylpiperazin-1-yl)-3-fluorobenzonitrile Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(C#N)C=C1F BRVBDVOTMCVCCE-UHFFFAOYSA-N 0.000 description 2
- HGXWRDPQFZKOLZ-UHFFFAOYSA-N 4-bromo-2-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC=C1C#N HGXWRDPQFZKOLZ-UHFFFAOYSA-N 0.000 description 2
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 2
- LUJBEFQVVXDCPL-UHFFFAOYSA-N 5-bromo-3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC(Br)=CN=C1C=O LUJBEFQVVXDCPL-UHFFFAOYSA-N 0.000 description 2
- BHXHRMVSUUPOLX-UHFFFAOYSA-N 5-fluoropyridine-2-carbonitrile Chemical compound FC1=CC=C(C#N)N=C1 BHXHRMVSUUPOLX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010024715 Liver transplant rejection Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 208000035977 Rare disease Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- PMGVOPYAMVOKIH-UHFFFAOYSA-N [6-(difluoromethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=C(C(F)F)N=C1 PMGVOPYAMVOKIH-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- FINPLSBBDVRBPA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-methoxy-2-methylpropane;2-phenylethanamine Chemical compound [Pd+]Cl.COC(C)(C)C.NCCC1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 FINPLSBBDVRBPA-UHFFFAOYSA-M 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 1
- RRWPWJDQLAPSMH-UHFFFAOYSA-N 1-[4-[4-(1-aminocyclopropyl)phenyl]piperazin-1-yl]ethanone Chemical compound NC1(CC1)C1=CC=C(C=C1)N1CCN(CC1)C(C)=O RRWPWJDQLAPSMH-UHFFFAOYSA-N 0.000 description 1
- RWJMIZKQNYQFJC-UHFFFAOYSA-N 1-[4-[4-(aminomethyl)-2-fluorophenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(CN)C=C1F RWJMIZKQNYQFJC-UHFFFAOYSA-N 0.000 description 1
- LIDWNGSETOOUBS-UHFFFAOYSA-N 1-[4-[4-(aminomethyl)phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(CN)C=C1 LIDWNGSETOOUBS-UHFFFAOYSA-N 0.000 description 1
- GLWDJPNUEWIAPP-UHFFFAOYSA-N 1-[6-[4-(aminomethyl)phenyl]-2,6-diazaspiro[3.3]heptan-2-yl]ethanone Chemical compound CC(=O)N1CC2(C1)CN(C2)C1=CC=C(CN)C=C1 GLWDJPNUEWIAPP-UHFFFAOYSA-N 0.000 description 1
- YHWFCFIXXMXRBF-UHFFFAOYSA-N 2,5-diiodopyridine Chemical compound IC1=CC=C(I)N=C1 YHWFCFIXXMXRBF-UHFFFAOYSA-N 0.000 description 1
- PFOYYSGBGILOQZ-UHFFFAOYSA-N 2-(2-methylpropanoyl)cyclohexan-1-one Chemical compound CC(C)C(=O)C1CCCCC1=O PFOYYSGBGILOQZ-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- UIIJZQVROQHLAP-UHFFFAOYSA-N 2-methyl-2-(2-methylbutan-2-yloxy)butane;sodium Chemical compound [Na].CCC(C)(C)OC(C)(C)CC UIIJZQVROQHLAP-UHFFFAOYSA-N 0.000 description 1
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QQVKGQDQOKQEKQ-UHFFFAOYSA-N 4-(2,6-diazaspiro[3.3]heptan-2-yl)benzonitrile Chemical compound N#Cc1ccc(cc1)N1CC2(CNC2)C1 QQVKGQDQOKQEKQ-UHFFFAOYSA-N 0.000 description 1
- VQHYDSBOUKNNHY-UHFFFAOYSA-N 4-(3,3-dimethylpiperazin-1-yl)benzonitrile 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.CC1(CN(CCN1)C1=CC=C(C#N)C=C1)C VQHYDSBOUKNNHY-UHFFFAOYSA-N 0.000 description 1
- BNKQZLHPSROYMO-UHFFFAOYSA-N 4-(4-acetyl-3,3-dimethylpiperazin-1-yl)benzonitrile Chemical compound C(C)(=O)N1C(CN(CC1)C1=CC=C(C#N)C=C1)(C)C BNKQZLHPSROYMO-UHFFFAOYSA-N 0.000 description 1
- AQYDDMNMTYEIGX-UHFFFAOYSA-N 4-(4-acetylpiperazin-1-yl)-2-fluorobenzonitrile Chemical compound CC(=O)N1CCN(CC1)c1ccc(C#N)c(F)c1 AQYDDMNMTYEIGX-UHFFFAOYSA-N 0.000 description 1
- LZSGDTPLNNOXMT-UHFFFAOYSA-N 4-(7-methyl-6-oxo-2,7-diazaspiro[3.4]octan-2-yl)benzonitrile Chemical compound CN1CC2(CN(C2)C2=CC=C(C#N)C=C2)CC1=O LZSGDTPLNNOXMT-UHFFFAOYSA-N 0.000 description 1
- AWFOXZCNAXHLEM-UHFFFAOYSA-N 5-(4-acetylpiperazin-1-yl)pyridine-2-carbonitrile Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(C#N)N=C1 AWFOXZCNAXHLEM-UHFFFAOYSA-N 0.000 description 1
- SWEPDKQKBBIAFY-UHFFFAOYSA-N 5-bromo-2-(difluoromethyl)-3-fluoropyridine Chemical compound FC(F)c1ncc(Br)cc1F SWEPDKQKBBIAFY-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229940126043 Galectin-3 inhibitor Drugs 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 229940122348 JNK1 inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 101150086964 LPAR1 gene Proteins 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 229940124789 MK2 inhibitor Drugs 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- QRIBJMRAHZSYNH-UHFFFAOYSA-N N#CC(C=C1)=CC=C1N1CC(C2)(CN2C(O)=O)C1 Chemical compound N#CC(C=C1)=CC=C1N1CC(C2)(CN2C(O)=O)C1 QRIBJMRAHZSYNH-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- NPIHYFCXNIDUJZ-UHFFFAOYSA-N [2-chloro-6-[2,6-di(propan-2-yloxy)phenyl]phenyl]-dicyclohexylphosphane Chemical group ClC=1C(=C(C=CC=1)C1=C(C=CC=C1OC(C)C)OC(C)C)P(C1CCCCC1)C1CCCCC1 NPIHYFCXNIDUJZ-UHFFFAOYSA-N 0.000 description 1
- YLJWJCLYBACGCA-UHFFFAOYSA-N [6-(difluoromethyl)-5-fluoropyridin-3-yl]methanol Chemical compound OCc1cnc(C(F)F)c(F)c1 YLJWJCLYBACGCA-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- DRNAQRXLOSUHBQ-UHFFFAOYSA-N cphos Chemical compound CN(C)C1=CC=CC(N(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 DRNAQRXLOSUHBQ-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DIIIJIQXQUZJID-UHFFFAOYSA-N methyl 6-(difluoromethyl)-5-fluoropyridine-3-carboxylate Chemical compound COC(=O)c1cnc(C(F)F)c(F)c1 DIIIJIQXQUZJID-UHFFFAOYSA-N 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- KFFUKMJVUSGHKC-UHFFFAOYSA-N tert-butyl 2-(4-cyanophenyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate Chemical compound C(OC(=O)N1CCC2(CN(C3=CC=C(C#N)C=C3)C2)CC1)(C)(C)C KFFUKMJVUSGHKC-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本發明係關於新穎嗒𠯤、其製備方法、含有其之醫藥組合物及其在療法,尤其在治療及/或預防由自分泌運動因子介導之疾病及病症中之用途。
Description
本發明係關於新穎嗒𠯤、其製備方法、含有其之醫藥組合物及其在療法,尤其在治療及/或預防由自分泌運動因子介導之疾病及病症中之用途。
自分泌運動因子(Autotaxin;ATX;ENPP2)為負責經由其溶血磷脂D活性將溶血磷脂醯膽鹼(LPC)水解成生物活性脂質溶血磷脂酸(LPA)的分泌酶。轉而,LPA藉由與六個GPCR (LPA受體1至6,LPAR1-6) (Houben AJ, 2011)相互作用來發揮其效果。ATX-LPA信號傳導參與例如血管新生、慢性發炎、自體免疫疾病、纖維化疾病、癌症進展及腫瘤轉移。舉例而言,作用於LPAR1之LPA誘發肺纖維母細胞遷移、增殖及分化;調節上皮及內皮障壁功能;及促進肺上皮細胞凋亡(Budd, 2013)。已顯示ATX抑制、LPAR1基因缺失及選擇性LPAR1拮抗劑在肺及皮膚之纖維化之臨床前模型中有效(Tager AM, 2008;Swaney J, 2010,Casetelino FV, 2016)。
在特發性肺纖維化(IPF)患者中,支氣管肺泡灌洗液中之LPA含量增加(Tager等人, 2008, Nat. Med.)且在人類纖維化肺組織中偵測到ATX之濃度增加(Oikonomou等人, 2012, AJRCMB)。IPF個體之呼出氣冷凝液中的LPA含量升高(Montesi等人, 2014_BMCPM),且穩定IPF患者之血清中的LPC增加2倍(Rindlisbacher等人, 2018, Resp. Res.)。
因此,增加的ATX含量及/或增加的LPA含量、改變之LPA受體表現及改變的對LPA之反應可影響與ATX-LPA信號傳導有關的許多病理生理學病況。
間質性肺病(ILD)之特徵在於肺氣囊之間的間質、組織及間隙之發炎及纖維化(du Bois, Nat. Rev. Drug Discov. 2010, 9, 129-140)。當肺損傷觸發異常的癒合反應時,可能發生ILD。因此,ILD亦包括進行性纖維化間質性肺病(PFILD),其中對肺損傷之反應變成進行性的、自我維持的且與原始臨床相關性或觸發無關。最突出的PF-ILD為特發性肺纖維化(IPF)及全身性硬化症-ILD(SSc-ILD)。
IPF為一種慢性纖維化之不可逆且最終致命的肺病,其特徵在於肺間質的進行性纖維化,導致肺容量減少及進行性肺功能不全。IPF的特徵亦在於稱為尋常型間質性肺炎(UIP)的特定組織病理學模式(Raghu等人, Am. J. Respir. Crit. Care Med. 183: 788-824.)。
全身性硬化症(SSc),亦稱作硬皮病,其為病因複雜之免疫調節風濕病。其為高死亡率之多器官異質疾病,其特徵在於廣泛纖維化、血管病變及抗各種細胞抗原的自體抗體。其為罕見病症,係具有較高未滿足醫療需求之罕見疾病。SSc之早期臨床症狀可不同。雷諾現象(Raynaud's phenomenon)及胃食道逆流常在疾病早期顯現(Rongioletti F等人, J Eur Acad Dermatol Venereol 2015; 29: 2399-404)。一些患者顯現發炎性皮膚病、手指浮腫、肌肉骨骼發炎或諸如疲乏之體質表現。患者皮膚中之過量膠原蛋白沈積使得皮膚變厚及變硬。在一些患者中,觀察到疾病的如肺纖維化、肺動脈高壓、腎衰竭或腸胃併發症的基於器官之表現。另外,免疫損害之最常見表現之一為存在含量異常之抗自身細胞核之自體免疫抗體(抗核抗體或ANA),其幾乎見於每個SSc患者中(Guiducci S等人, Isr Med Assoc J 2016; 18: 141-43)。ILD及肺動脈高壓(PAH)為SSc患者之最常見死因(Tyndall AJ等人 Ann Rheum Dis 2010; 69: 1809-15)。
SSc患者分類為兩個主要疾病亞群:彌漫型皮膚全身性硬化症及侷限型皮膚全身性硬化症(LeRoy EC等人, J Rheumatol 1988; 15:202-5)。三種臨床特徵,即過度纖維化(瘢痕形成)、血管病變及自體免疫,似乎是導致表徵SSc之不同表現的過程之基礎。SSc當前被視為一種結締組織損傷之調節異常或修復功能異常的表現(Denton CP等人, Lancet 2017; 390: 1685-99)。
因此,期望提供有效ATX抑制劑。
各種結構類別之ATX抑制劑綜述於D. Castagna等人 (J.Med.Chem. 2016, 59, 5604-5621)中。WO2014/139882揭示作為ATX抑制劑的化合物,其具有通用結構式。
本文中之實例2進一步作為正在進行臨床評估之用於治療特發性肺纖維化的首創ATX抑制劑揭示於N. Desroy等人 (J.Med.Chem. 2017, 60, 3580-3590,如實例11)中。C. Kuttruff等人 (ACS Med. Chem. Lett. 2017, 8, 1252-1257)揭示ATX抑制劑BI-2545 (實例19)顯著降低活體內LPA含量。
本發明提供新穎嗒𠯤,其為自分泌運動因子之意外高效之抑制劑(分析A),其特徵進一步在於
-在人類全血中之高效力(分析B),及
-LPA歷經若干小時在活體內之血漿濃度水準的顯著降低(分析C)。
本發明之化合物適用作治療或預防如下疾病或病況之藥劑,其中ATX活性及/或LPA信號傳導參與疾病之病源學或病理學中或以其他方式與疾病之至少一種症狀相關。ATX-LPA信號傳導參與例如血管新生、慢性發炎、自體免疫疾病、纖維化疾病、癌症進展及腫瘤轉移。
本發明之化合物在以下參數之組合方面優於先前技術中所揭示之彼等化合物:
-作為ATX抑制劑之效力,
-作為ATX抑制劑在類全血中之效力,
-在活體內歷經若干小時降低LPA之血漿濃度水準。
ATX為可溶血漿蛋白,其在肝素化全血中具有活性。其受質LPC非常充足,其濃度在µM範圍內。因此,生理學受質濃度下之全血分析為高度相關之分析,對於ATX抑制劑在活體內之功效具有預測性。
活體內LPA降低係藉由在本發明之化合物之經口給藥後量測LPA之血漿濃度來測定的。LPA為生物活性極強之脂質,其經由LPA受體1至6以濃度依賴性方式有效地活化下游路徑。經由ATX抑制之LPA形成之明顯及持續阻斷係藉由在化合物給藥後8小時量測LPA降低程度來評定的。因此,8 h時血漿LPA之較大降低高度指示LPA受體之活體內作用之功效及持續時間以及持續目標接合。
本發明之化合物結構上不同於WO2014/139882中之實例2及12以及ACS Med. Chem. Lett. 2017, 8, 1252-1257中之實例19,此係因為其含有在3位及6位具有取代基的嗒𠯤中心核。此結構差異意外地得到以下之優良組合:(i) ATX抑制、(ii)人類全血中之ATX抑制及(iii) LPA在活體內歷經若干小時之血漿濃度水準之降低。
因此,本發明之化合物展現較高活體內目標接合且可預期在人體內具有更高功效。
本發明提供新穎式(I)化合物
其中
A為經氟及F1-7
-氟-C1-3
烷基組成之群中的一或兩個成員取代之吡啶基;
E係選自由以下組成之群:視情況經氟及F1-7
-氟-C1-3
烷基組成之群中的一或兩個成員取代之苯基及吡啶基;
K係選自由以下組成之群:;
R3
係選自由R4
(O)C-、氧雜環丁烷基、甲基、R5
(O)C(CH3
)N-及R5
(O)CHN-組成之群;
R4
為甲基;
R5
為甲基。
本發明之另一實施例係關於一種式(I)化合物,其中A為經F、及F1-3
-氟-C1
烷基組成之群中的一或兩個成員取代之吡啶基;且取代基E及K如在前述實施例中所定義。
本發明之另一實施例係關於一種式(I)化合物,其中A為經F、F2
HC及F3
C組成之群中的一或兩個成員取代之吡啶基;且取代基E及K如在前述實施例中所定義。
本發明之另一實施例係關於一種式(I)化合物,其中E係選自由組成之群:視情況經F、F2
HC及F3
C組成之群中的一或兩個成員取代之苯基及吡啶基;且取代基A及K如在前述實施例中之任一者中所定義。
本發明之另一實施例係關於一種式(I)化合物,其中E係選自由以下組成之群:視情況經F及F3
C組成之群中的一或兩個成員取代之苯基及吡啶基;且取代基A及K如在前述實施例中之任一者中所定義。
另一實施例係關於一種醫藥組合物,其包含至少一種根據本發明之式I化合物或其醫藥學上可接受之鹽,及一或多種醫藥學上可接受之賦形劑。
另一實施例係關於一種根據本發明之式(I)化合物,其用作藥物。
所使用術語及定義
應當給未在本文中特別定義之術語賦予熟習此項技術者將依據本發明及上下文而賦予其之含義。然而,如本說明書中所使用,除非相反地說明,否則以下術語具有所指定之含義且將遵守以下定則。
在下文定義之基團(group/radical)或部分中,通常在基團之前指定碳原子數目,例如C1-6
烷基意謂具有1至6個碳原子之烷基。一般而言,在如HO、H2
N、(O)S、(O)2
S、NC(氰基)、HOOC、F3
C或類似基團之基團中,熟習此項技術者可根據基團自身之自由價發現基團與分子之連接點。對於包含兩個或更多個亞基的組合基團,最後命名之亞基為基團連接點,例如取代基「芳基-C1-3
烷基」意謂芳基與C1-3
烷基鍵結,C1-3
烷基與核心或與取代基所連接之基團鍵結。
在本發明之化合物以化學名稱及化學式形式描繪之情況下,若有任何不一致,則應以化學式為準。星號可用於在子式中以指示連接至如所定義之核心分子的鍵。
取代基原子之記數始於最接近核心或最接近取代基所連接之基團的原子。
星號可用於子式中以指示連接至如所定義之核心分子的鍵。
如本文所使用之術語「經取代」意謂在指定原子上之任何一或多個氫經來自所指示基團之選項置換,其限制條件為不超過指定原子之正常價且取代產生穩定化合物。
術語「C1-n
烷基」(其中n為選自2、3、4、5或6,較佳4或6之整數)單獨或與另一個基團組合表示具有1至n個C原子之非環狀飽和分支鏈或直鏈烴基。舉例而言,術語C1-5
烷基包含基團H3
C-、H3
C-CH2
-、H3
C-CH2
-CH2
-、H3
C-CH(CH3
)-、H3
C-CH2
-CH2
-CH2
-、H3
C-CH2
-CH(CH3
)-、H3
C-CH(CH3
)-CH2
-、H3
C-C(CH3
)2
-、H3
C-CH2
-CH2
-CH2
-CH2
-、H3
C-CH2
-CH2
-CH(CH3
)-、H3
C-CH2
-CH(CH3
)-CH2
-、H3
C-CH(CH3
)-CH2
-CH2
-、H3
C-CH2
-C(CH3
)2
-、H3
C-C(CH3
)2
-CH2
-、H3
C-CH(CH3
)-CH(CH3
)-及H3
C-CH2
-CH(CH2
CH3
)-。
術語「鹵素」表示氯、溴、碘及氟。添加至「烷基」、「伸烷基」或「環烷基」(飽和或不飽和)的術語「鹵基」為其中一或多個氫原子經選自氟、氯或溴,較佳為氟及氯,尤佳為氟之鹵素原子置換的此類烷基或環烷基。實例包括:H2
FC-、HF2
C-、F3
C-。
除非特定指示,否則在整篇說明書及隨附申請專利範圍中,給定化學式或名稱將涵蓋其互變異構體及所有立體、光學及幾何異構體(例如對映異構體、非對映異構體、E/Z異構體等)及外消旋體;以及不同比例之分開的對映異構體之混合物、非對映異構體之混合物或此類異構體及對映異構體存在之任何上述形式之混合物;以及其鹽,包括其醫藥學上可接受之鹽;及其溶劑合物,諸如水合物,包括游離化合物之溶劑合物或化合物之鹽的溶劑合物。
一般而言,可根據熟習此項技術者已知之合成原理來獲得實質上純的立體異構體,例如藉由分離對應混合物,藉由使用立體化學純之起始物質及/或藉由立體選擇性合成。此項技術中已知如何製備光學活性形式,諸如藉由外消旋形式之解析或藉由合成,例如自光學活性起始物質開始及/或藉由使用對掌性試劑。
可經由不對稱合成來製備本發明之對映異構性純化合物或中間物,例如藉由製備及後續分離可藉由已知方法(例如藉由層析分離或結晶)分離的適當非對映異構化合物或中間物,及/或藉由使用對掌性試劑,諸如對掌性起始物質、對掌性催化劑或對掌性助劑。
此外,熟習此項技術者已知如何自對應外消旋混合物製備對映異構純化合物,諸如藉由在對掌性固定相上層析分離對應外消旋混合物;或藉由使用適當解析劑來解析外消旋混合物,例如藉助於外消旋化合物與光學活性酸或鹼形成非對映異構鹽,隨後解析該等鹽及自該鹽釋放所需化合物;或藉由進行對應外消旋化合物與光學活性對掌性輔助試劑之衍生化,隨後分離非對映異構體及移除對掌性輔助基團;或藉由動力學解析外消旋體(例如,藉由酶解);藉由在適合的條件下自同形異向晶體之聚結物進行對映選擇性結晶;或藉由在光學活性對掌性助劑之存在下自適合的溶劑進行(部分)結晶。
片語「醫藥學上可接受」在本文中用於指代合理醫學判斷範疇內,適合使用而無過度毒性、刺激、過敏反應或其他問題或併發症且與合理益處/風險比相匹配之彼等化合物、物質、組合物及/或劑型。
如本文所使用,「醫藥學上可接受之鹽」指代所揭示之化合物的衍生物,其中親本化合物形成鹽或含酸或鹼之錯合物。
與含有鹼性部分之親本化合物形成醫藥學上可接受之鹽之酸的實例包括無機酸或有機酸,諸如苯磺酸、苯甲酸、檸檬酸、乙磺酸、反丁烯二酸、龍膽酸(gentisic acid)、氫溴酸、氫氯酸、順丁烯二酸、蘋果酸、丙二酸、杏仁酸、甲磺酸、4-甲基-苯磺酸、磷酸、柳酸、丁二酸、硫酸或酒石酸。
與含有酸性部分之親本化合物形成醫藥學上可接受之鹽的陽離子及鹼之實例包括Na+
、K+
、Ca2+
、Mg2+
、NH4 +
、L-精胺酸、2,2'-亞胺雙乙醇、L-離胺酸、N
-甲基-D-葡糖胺或參(羥基甲基)-胺基甲烷。
本發明之醫藥學上可接受之鹽可藉由習知化學方法由含有鹼性或酸性部分之親本化合物合成。一般而言,可藉由使此等化合物之游離酸或游離鹼形式與足量適當鹼或酸之水溶液或有機稀釋劑溶液(如乙醚、乙酸乙酯、乙醇、異丙醇或乙腈或其混合物)反應來製備此類鹽。
除了例如適用於純化或分離本發明之化合物(例如三氟乙酸鹽)之上文提及之彼等酸以外的其他酸之鹽亦包含本發明之一部分。
生物分析
化合物之生物活性係藉由以下方法測定:
分析 A : 生物化學 ATX 分析
將5 nM重組ATX (Cayman Chemicals)補充至含有3 mM KCl、1 mM CaCl2、1 mM MgCl2、0.14 mM NaCl及0.1%牛血清白蛋白之50 mM Tris緩衝液(pH 8.0)中。將測試化合物溶解於DMSO中且在0.1 nM至10 µM之範圍內進行測試。藉由添加2.5 µL 10 µM 18:1 LPC (Avanti Lipids, Alabaster, AL, USA)起始酶促反應(22.5 µL)。在室溫下培育2 h後,藉由添加含有500 nM 20:4 LPA之20 µL水作為內標及用於萃取LPA之100 µL 1-丁醇來停止反應。隨後,在4000 rpm、4℃下離心培養盤2 min。將所得上層丁醇相直接用於注入RapidFire系統(Agilent)。
將RapidFire自動取樣器耦接至二元泵(Agilent 1290)及Triple Quad 6500 (ABSciex, Toronto, Canada)。此系統配備10 µL迴路、5 µL Waters Atlantis HILIC濾筒(Waters, Elstree, UK)、作為溶離劑A的含有10 mM乙酸銨之90%乙腈及作為溶離劑B的含有10 mM乙酸銨之40%乙腈。細節參見(Bretschneider等人, SLAS Discovery, 2017)。在源溫度為550℃,氣簾= 35,氣體1 = 65及氣體2 = 80之負模式中操作MS。測定各別LPA之以下轉變及MS參數(DP:去簇電位及CE:碰撞能量):
在435.2/152.8、DP = −40、CE = −28下之18:1 LPA及在457.2/152.8、DP = −100、CE = −27下之20:4 LPA)。
監測18:1 LPA之形成且評估其與20:4 LPA之比率。
表1:如在分析A中獲得之本發明化合物的生物資料。
表2:如在分析A中獲得之先前技術化合物(WO2014/139882中之實例2
及12
)的生物資料。
表3:如在分析A中獲得之先前技術化合物(在ACS Med. Chem. Lett. 2017, 8, 1252-1257中之實例19
)的生物資料。
實例 | 人類ATX LPA IC50 [nM] | 實例 | 人類ATX LPA IC50 [nM] |
1.1 | 3.4 | 2.12 | 3.5 |
1.2 | 2.9 | 2.13 | 4.0 |
1.3 | 1.5 | 2.14 | 4.4 |
1.4 | 3.3 | 2.15 | 2.2 |
1.5 | 3.9 | 2.16 | 10.4 |
1.6 | 6.5 | 2.17 | 5.2 |
1.7 | 1.6 | 2.18 | 9.2 |
2.1 | 2.3 | 2.19 | 2.4 |
2.2 | 3.0 | 2.20 | 2.9 |
2.3 | 2.2 | 2.21 | 2.4 |
2.4 | 1.9 | 2.22 | 6.2 |
2.5 | 2.5 | 2.23 | 3.9 |
2.6 | 1.8 | 3 | 2.9 |
2.7 | 1.9 | 4 | 8.6 |
2.8 | 2.0 | 5 | 7.0 |
2.9 | 3.7 | - | - |
2.10 | 1.8 | - | - |
2.11 | 3.8 | - | - |
WO2014/139882中之實例 | 人類ATX LPA IC50 [nM] |
2 | 5 |
12 | 2 |
ACS Med. Chem. Lett. 2017, 8, 1252-1257中之實例 | 人類ATX LPA IC50 [nM] |
19 | 2.2 |
分析 B : 全血 ATX 分析
將45 µL人類全血補充5 µL測試化合物,溶解於磷酸鹽緩衝生理鹽水中(濃度範圍在0.12 nM-100 µM)。在37℃培育此混合物1 h且藉由添加含有30 mM檸檬酸(pH 4)及1 µM 17:0 LPA (內標)之100 µL 40 mM磷酸氫二鈉緩衝液停止。藉由添加500 µL 1-丁醇萃取LPA,接著在4000 rpm、4℃離心10 min。自所得有機上清液,將200 µL等分試樣轉移至96深孔培養盤中且轉移至基於RapidFire之MS/MS量測。
將RapidFire自動取樣器耦接至二元泵(Agilent 1290)及Triple Quad 6500 (ABSciex, Toronto, Canada)。此系統配備10 µL迴路、5 µL Waters Atlantis HILIC濾筒(Waters, Elstree, UK)、作為溶離劑A的含有10 mM乙酸銨之90%乙腈及作為溶離劑B的含有10 mM乙酸銨之40%乙腈。細節參見(Bretschneider等人, SLAS Discovery, 2017, 22, 425-432)。在源溫度為550℃,氣簾= 35,氣體1 = 65及氣體2 = 80之負模式中操作MS。測定各別LPA之以下轉變及MS參數(DP:去簇電位及CE:碰撞能量):在433.2/152.8、DP = −150、CE = −27下之18:2 LPA及在423.5/152.8、DP = −100下之17:0 LPA。
監測18:2 LPA之形成且評估其與17:0 LPA之比率。
表4:如在分析B中獲得之本發明之化合物的生物資料。
表5:如在分析B中獲得之先前技術化合物(WO2014/139882中之實例2
及12
)的生物資料。
表6:如在分析B中獲得之先前技術化合物(ACS Med. Chem. Lett. 2017, 8, 1252-1257中之實例19
)的生物資料。
實例 | 人類全血LPA IC50 [nM] | 實例 | 人類全血LPA IC50 [nM] |
1.1 | 1.7 | 2.12 | 4.3 |
1.2 | 1.0 | 2.13 | 4.1 |
1.3 | 1.6 | 2.14 | 2.8 |
1.4 | 2.8 | 2.15 | 9.3 |
1.5 | 2.0 | 2.16 | 5.1 |
1.6 | 8.7 | 2.17 | 3.5 |
1.7 | 12.4 | 2.18 | 4.1 |
2.1 | 4.7 | 2.19 | 2.0 |
2.2 | 4.7 | 2.20 | 3.7 |
2.3 | 4.4 | 2.21 | 1.4 |
2.4 | 6.8 | 2.22 | 3.9 |
2.5 | 4.0 | 2.23 | 3.6 |
2.6 | 3.2 | 3 | 1.9 |
2.7 | 7.0 | 4 | 7.1 |
2.8 | 2.4 | 5 | 7.5 |
2.9 | 4.1 | - | - |
2.10 | 2.2 | - | - |
2.11 | 4.0 | - | - |
WO2014/139882中之實例 | 人類全血LPA IC50 [nM] |
2 | 370 |
12 | 50 |
ACS Med. Chem. Lett. 2017, 8, 1252-1257中之實例 | 人類全血LPA IC50 [nM] |
19 | 29 |
分析 C :活體內
將測試物質溶解於補充有0.015% Tween 80之0.5%纖維素羥乙基醚(natrosol)中以供按5 mg/kg之劑量經口施用於大鼠。在化合物投與之前及施用8小時後使用EDTA作為凝血劑於冰上收集血液樣本。隨後,藉由離心製備血漿且儲存於-20℃下直至分析。
藉由使用由Scherer等人 (Clinical chemistry 2009, 55, 1218-22)所描述之程序自血漿樣本萃取LPA。將35 µL肝素化血漿與含有30 mM檸檬酸(pH 4)及1 µM 17:0 LPA (內標)之200 µL 40 mM磷酸氫二鈉緩衝液混合。隨後,添加500 µL丁醇且劇烈振盪10 min。然後在4000 rpm、4℃下離心樣本10 min。將500 µL上層有機相轉移至新的96深孔培養盤且用15 psi之平緩氮氣流蒸發45 min。在LC-MS分析之前將所得殘餘物溶解於100 µL乙醇中。
用於活體內樣本之分析的 LC-MS 方法
Triple Quad 6500 (ABSciex, Toronto, Canada)配備Agilent 1290 LC系統(Agilent, Santa Clara, CA)、CTC自動取樣器及Atlantis 50×2.1 mm 3 µm HILIC LC管柱(Waters, Elstree, UK)。溶離劑A含有0.2%甲酸及50 mM甲酸銨水溶液,而溶離劑B由含0.2%甲酸之乙腈組成。LC梯度自95%溶劑B開始且在1.5 min內減少至75%溶劑B及在0.2分鐘內減少至50%溶劑B,其中流動速率自500 µL·min-1
進一步提高至700 µL·min-1
。在1.8 min,將溶劑B設定回至95%且保持恆定0.7 min以使管柱重新平衡。監測以下LPA物種(DP:去簇電位及CE:碰撞能量):在409.2/152.8、DP = −150、CE = −28下之16:0 LPA;在437.3/152.8、DP = −60、CE = −28下之18:0 LPA;在435.2/152.8、DP = −40、CE = −28下之18:1 LPA;在433.2/152.8、DP = −150、CE = −28下之18:2 LPA;在457.2/152.8、DP = −100、CE = −29下之20:4 LPA;及在423.5/152.8、DP = −100、CE = -36下之17:0 LPA。
基於施用測試化合物之前的基線LPA含量計算LPA消耗百分比。LPA之總和指代物種16:0、18:0、18:1、18:2及20:4。
表7:如在分析C中獲得之本發明之化合物的生物資料。
表8:如在分析C中獲得之先前技術化合物(WO2014/139882中之實例2
及12
)的生物資料。
表9:如在分析C中獲得之先前技術化合物(ACS Med. Chem. Lett. 2017, 8, 1252-1257中之實例19
)的生物資料。
實例 | 在8 h時之LPA降低[%] |
1.1 | 96.5 |
1.2 | 96.7 |
2.2 | 94.1 |
2.5 | 95.9 |
2.12 | 94.6 |
3 | 99.9 |
實例 | 在8 h時之LPA降低[%] |
2 | 58.1 |
12 | 60.3 |
實例 | 在8 h時之LPA降低[%] |
19 | 40.7 |
治療方法
本發明係有關通式(I)化合物,其適用於預防及/或治療與ATX及/或LPA之生物活性相關或藉由ATX及/或LPA之生物活性調節的疾病及/或病況,包括但不限於治療及/或預防發炎性病況、纖維化疾病、呼吸系統病況、腎病、肝病、血管及心血管病況、癌症、眼部病況、代謝病況、膽汁鬱積性及其他形式之慢性搔癢病以及急性及慢性器官移植排斥及神經系統病況。
通式(I)化合物適用於預防及/或治療發炎性病況,包括但不限於薛格連氏症候群(Sjögren's syndrome)、關節炎、骨關節炎、多發性硬化症、全身性紅斑狼瘡、發炎性腸病、諸如慢性阻塞性肺病(COPD)及慢性哮喘之發炎性氣道疾病;纖維化疾病,包括但不限於間質性肺病(ILD) (包括諸如特發性肺纖維化(IPF)及SSC-ILD之進行性纖維化間質性肺病(PFILD))、家族性間質性肺病心肌及血管纖維化、腎纖維化、肝纖維化、肺纖維化、皮膚纖維化、膠原血管疾病(包括全身性硬化症(SSc)及包囊性腹膜炎);呼吸系統病況,包括但不限於不同病源學之彌漫型實質性肺病,包括醫原性的藥物誘發性纖維化、職業性及/或環境誘發性纖維化、全身性疾病及血管炎、肉芽腫病(類肉瘤病、過敏性肺炎);腎病,包括但不限於有或無蛋白尿之急性腎損傷及慢性腎病,包括末期腎病(ESRD)、局灶節段性腎小球硬化症、IgA腎病變、血管炎/全身性疾病以及急性及慢性腎移植排斥;肝病,包括但不限於肝硬化、肝淤血、包括搔癢病之膽汁鬱積性肝病、原發性膽汁性膽管炎、非酒精性脂肪變性肝炎以及急性及慢性肝移植排斥;血管病況,包括但不限於動脈粥樣硬化、血栓性血管疾病以及血栓性微血管病、增生性動脈病(諸如由黏液性細胞外基質圍繞之肌內膜細胞腫脹及結節性增厚)、內皮細胞功能不良;心血管病況,包括但不限於急性冠狀動脈症候群、冠心病、心肌梗塞、動脈性高血壓及肺性高血壓、諸如心房微顫之心律不整、中風及其他血管損傷;癌症及癌轉移,包括但不限於乳癌、卵巢癌、肺癌、前列腺癌、間皮瘤、神經膠質瘤、肝癌、胃腸癌及其進展性及轉移性侵襲;眼部病況,包括但不限於增生性及非增生性(糖尿病性)視網膜病變、乾性及濕性年齡相關黃斑部變性(AMD)、黃斑水腫、中央動脈/靜脈閉塞、創傷性損傷、青光眼;代謝病況,包括但不限於肥胖、血脂異常及糖尿病;神經系統病況,包括但不限於神經痛、阿茲海默氏症(Alzheimer's disease)、精神分裂症、神經炎症(例如,星形膠質化)、周邊神經病變及/或自主(糖尿病性)神經病變。
因此,本發明係關於一種通式(I)化合物,其用作藥物。
此外,本發明係關於通式(I)化合物之用途,其用於治療及/或預防與ATX及/或LPA之生物活性相關聯或藉由ATX及/或LPA之生物活性調節的疾病及/或病況。
此外,本發明係關於通式(I)化合物之用途,其用於治療及/或預防與ATX及/或LPA之生物活性相關聯或藉由ATX及/或LPA之生物活性調節的疾病及/或病況,包括但不限於發炎性病況、纖維化疾病、呼吸系統病況、腎病、肝病、血管及心血管病況、癌症、眼部病況、代謝病況、膽汁鬱積性及其他形式之慢性搔癢病以及急性及慢性器官移植排斥及神經系統病況。
此外,本發明係關於通式(I)化合物之用途,其用於治療及/或預防發炎性病況,包括但不限於薛格連氏症候群、關節炎、骨關節炎、多發性硬化症、全身性紅斑狼瘡、發炎性腸病、諸如慢性阻塞性肺病(COPD)及慢性哮喘之發炎性氣道疾病;纖維化疾病,包括但不限於間質性肺病(ILD) (包括諸如特發性肺纖維化(IPF)及SSC-ILD之進行性纖維化間質性肺病(PFILD))、家族性間質性肺病心肌及血管纖維化、腎纖維化、肝纖維化、肺纖維化、皮膚纖維化、膠原血管疾病(包括全身性硬化症(SSc)及包囊性腹膜炎);呼吸系統病況,包括但不限於不同病源學之彌漫型實質性肺病,包括醫原性的藥物誘發性纖維化、職業性及/或環境誘發性纖維化、全身性疾病及血管炎、肉芽腫病(類肉瘤病、過敏性肺炎);腎病,包括但不限於有或無蛋白尿之急性腎損傷及慢性腎病,包括末期腎病(ESRD)、局灶節段性腎小球硬化症、IgA腎病變、血管炎/全身性疾病以及急性及慢性腎移植排斥;肝病,包括但不限於肝硬化、肝淤血、包括搔癢病之膽汁鬱積性肝病、原發性膽汁性膽管炎、非酒精性脂肪變性肝炎以及急性及慢性肝移植排斥;血管病況,包括但不限於動脈粥樣硬化、血栓性血管疾病以及血栓性微血管病、增生性動脈病(諸如由黏液性細胞外基質圍繞之肌內膜細胞腫脹及結節性增厚)、內皮細胞功能不良;心血管病況,包括但不限於急性冠狀動脈症候群、冠心病、心肌梗塞、動脈性高血壓及肺性高血壓、諸如心房微顫之心律不整、中風及其他血管損傷;癌症及癌轉移,包括但不限於乳癌、卵巢癌、肺癌、前列腺癌、間皮瘤、神經膠質瘤、肝癌、胃腸癌及其進展性及轉移性侵襲;眼部病況,包括但不限於增生性及非增生性(糖尿病性)視網膜病變、乾性及濕性年齡相關黃斑部變性(AMD)、黃斑水腫、中央動脈/靜脈閉塞、創傷性損傷、青光眼;代謝病況,包括但不限於肥胖、血脂異常及糖尿病;神經系統病況,包括但不限於神經痛、阿茲海默氏症、精神分裂症、神經炎症(例如,星形膠質化)、周邊神經病變及/或自主(糖尿病性)神經病變。
在另一態樣中,本發明係關於一種通式(I)化合物,其用於治療及/或預防上文所提及之疾病及病況。
在另一態樣中,本發明係關於通式(I)化合物之用途,其用於製備治療及/或預防上文所提及之疾病及病況的藥物。
在本發明之另一態樣中,本發明係關於用於治療或預防上文所提及之疾病及病況的方法,該方法包含向人類投與有效量的通式(I)化合物。
醫藥組合物
用於投與式(I)化合物之適合製劑對於一般技術者而言將顯而易見,且包括例如錠劑、丸劑、膠囊、栓劑、口含錠、糖衣錠、溶液、糖漿、酏劑、藥囊、可注射劑、吸入劑及粉劑等。
可例如藉由將一或多種式I化合物與已知賦形劑(例如,惰性稀釋劑、載劑、崩解劑、佐劑、界面活性劑、黏合劑及/或潤滑劑)混合來獲得適合錠劑。
組合療法
根據本發明之化合物可與其他已知用於此項技術中之治療選項組合,使得使用至少兩種有效量的活性化合物治療本發明同時適用之適應症。儘管組合療法較佳地包括同時向患者投與兩種活性化合物,但並非一定同時向患者投與化合物,而是有效量的個別化合物將同時存在於患者中。根據本發明之化合物可與一或多種如本文另外描述之組合搭配物一起投與。
因此,本發明提供根據前述實施例中任一項之式(I)化合物,其特徵在於除用一或多種來自由IL6調節劑、抗IL6R調節劑及IL13/IL-4 JAKi調節劑組成之清單的抗炎分子治療之外,亦投與式(I)化合物。
根據另一態樣,本發明提供根據前述實施例中任一項之式(I)化合物,其特徵在於除用一或多種來自由以下組成之清單的抗纖維化分子治療之外亦投與式(I)化合物:CB2促效劑、TGF調節劑、FGFR調節劑、VEGFR抑制劑、PDGFR抑制劑、FGF調節劑、αvβ6整合素調節劑、抗CTGF抗體、ROCK2抑制劑、rhPTX-2 (正五聚素蛋白-2;Pentraxin-2)、JNK1抑制劑、LOXL2抑制劑、半乳糖凝集素3抑制劑、MK2抑制劑、Wnt路徑抑制劑、TGFR抑制劑、PDE4調節劑、TRPA1抑制劑及微RNA調節劑。
根據另一態樣,本發明提供根據前述實施例中任一項之式(I)化合物,其特徵在於除尼達尼布(nintedanib)之外,亦投與式(I)化合物。
根據另一態樣,本發明提供根據前述實施例中任一項之式(I)化合物,其特徵在於除吡非尼酮(pirfenidone)之外,亦投與式(I)化合物。
製備
可使用熟習此項技術者已知且描述於有機合成文獻中之合成方法來獲得根據本發明之化合物。較佳地,與下文更充分解釋的製備方法類似地,尤其如實驗部分中所描述獲得化合物。
用於製備根據本發明之化合物的通用製程對於研究以下流程之熟習此項技術者將變得顯而易見。可藉由描述於文獻或本文中之方法製備或可以類似或相似方式製備起始物質。可使用習知保護基來保護起始物質或中間物中之任何官能基。此等保護基可使用熟習此項技術者熟悉之方法在反應序列內之適合階段裂解。
可藉由鹵化嗒𠯤或三氟甲磺酸嗒𠯤酯(II)與胺(III)之鈀介導布赫瓦爾德反應(Buchwald reaction)或銅介導烏爾曼反應(Ullmann reaction)製備通式(I)化合物,其中X為表示例如Cl、Br、I或OTf(三氟甲磺酸酯)之離去基。
可替代地藉由鹵化嗒𠯤或三氟甲磺酸嗒𠯤酯(VIII)與乙醇(VII)之鈀介導布赫瓦爾德反應或銅介導烏爾曼反應製備通式(I)化合物,其中X為表示例如Cl、Br、I或OTf(三氟甲磺酸酯)之離去基。
實例 實驗部分
以下實例意欲說明本發明而不對其進行限制。術語「環境溫度」及「室溫」可互換使用表示約20℃之溫度。
縮寫:
9-BBN | 9-硼雜雙環(3.3.1)壬烷 |
aq. | 水溶液 |
ACN | 乙腈 |
AcOH | 乙酸 |
Boc | 第三丁氧羰基 |
Brett Phos | 2-(二環己基膦基)-3,6-二甲氧基-2'-4'-6'-三異丙基-1,1'-聯苯 |
Brett Phos Pd G3 | 甲烷磺酸(2-二環己基膦基-3,6-二甲氧基-2',4',6'-三異丙基-1,1'-聯苯)(2'-胺基-1,1'-聯苯-2-基)鈀(II) |
℃ | 攝氏度 |
CDI | 羰基二咪唑 |
CO | 一氧化碳 |
conc. | 濃縮 |
CPHOS Pd G3 | 甲烷磺酸[(2-二環己基膦基-2',6'-雙(N,N-二甲基胺基)-1,1'-聯苯)-2-(2'-胺基-1,1'-聯苯)]鈀(II) |
CuI | 碘化銅(I) |
Cy | 環己烷 |
d | 天 |
DCM | 二氯甲烷 |
DIPE | 二異丙基醚 |
DIPEA | N,N -二異丙基乙胺 |
DMA | N,N -二甲基乙醯胺 |
DMF | N,N -二甲基甲醯胺 |
DMI | 1.3-二甲基-2-咪唑啶酮 |
DMSO | 二甲亞碸 |
dppf | 1,1`-雙(二苯基膦基)二茂鐵 |
EE | 乙酸乙酯 |
ESI-MS | 電噴霧電離質譜 |
EtOAc | 乙酸乙酯 |
EtOH | 乙醇 |
Ex. | 實例 |
Eq | 當量 |
g | 公克 |
h | 小時 |
HATU | 六氟磷酸N,N,N',N'-四甲基-O-(7-氮雜苯并三唑-1-基)鈾 |
HCl | 氯化氫 |
HPLC | 高效液相層析 |
JOSIPHOS SL-J009-1 Pd G3 | 甲烷磺酸{(R)-1-[(Sp)-2-(二環己基膦基)二茂鐵基]乙基二第三丁基膦}[2-(2'-胺基-1,1'-聯苯)]鈀(II) |
K2 CO3 | 碳酸鉀 |
KH2 PO4 | 磷酸二氫鉀 |
KHSO4 | 硫酸氫鉀 |
LiBH4 | 硼氫化鋰 |
L | 公升 |
L-selectride | 三第二丁基硼氫化鋰 |
M | 莫耳重量/g/mol |
MeOH | 甲醇 |
MgSO4 | 硫酸鎂 |
mg | 毫克 |
MgSO4 | 硫酸鎂 |
min | 分鐘 |
mL | 毫升 |
mmol | 毫莫耳 |
N | 1mol/L |
NaB(OAc)3 H | 三乙醯氧基硼氫化鈉 |
NaCl | 氯化鈉 |
NaH | 氫化鈉 |
NaHCO3 | 碳酸氫鈉 |
NaOAc | 乙酸鈉 |
NaOH | 氫氧化鈉 |
NaOtAm | 第三戊醇鈉 |
NaOtBu | 第三丁醇鈉 |
Na2 SO4 | 硫酸鈉 |
Na2 S2 O3 | 硫代硫酸鈉 |
Na2 SO4 | 硫酸鈉 |
NEt3 | 三乙胺 |
NH4 Cl | 氯化銨 |
NH4 OH | 氫氧化銨 |
NMP | N-甲基-2-吡咯啶酮 |
No. | 編號 |
Pd2 (dba)3 | 參(二苯亞甲基丙酮)二鈀(0) |
Pd/C | 鈀/活性碳 |
psi | 磅/平方吋 |
PTK | 相轉移濾筒 |
RP | 逆相 |
RT | 室溫(約20℃) |
Rt | 滯留時間 |
RUPHOS pallada-cycle | 氯-(2-二環己基膦基-2',6'-二異丙氧基-1,1'-聯苯)[2-(2-胺基乙基)苯基]鈀(II)-甲基-第三丁基乙醚加合物 |
sat. | 飽和 |
SFC | 超臨界流體層析 |
tBME | 第三丁基甲醚 |
TEA | 三乙胺 |
TFA | 三氟乙酸 |
THF | 四氫呋喃 |
Vol.-% | 體積百分比 |
XANTPHOS | 4,5-雙(二苯基膦基)-9,9-二甲基二苯并哌喃 |
XPHOS Pd G3 | 甲烷磺酸(2-二環己基膦基-2',4',6'-三異丙基-1,1'-聯苯)[2-(2'-胺基-1,1'-聯苯)]鈀(II) |
X-Phos | (2-二環己基膦基-2',4',6'-三異丙基-1,1'-聯苯) |
製備起始化合物 實例 I 實例 I.1 3-{[6-( 二氟甲基 ) 吡啶 -3- 基 ] 甲氧基 }-6- 碘嗒 𠯤
將含17.70 g (53.33 mmol) 3,6-二碘嗒𠯤(CAS編號20698-04-8)及8.50 g (53.41 mmol) [6-(二氟甲基)吡啶-3-基]甲醇(CAS編號946578-33-2)之25 mL THF冷卻至0℃且添加2.33 g (53.33 mmol)氫化鈉(55%純度)。將反應混合物在RT下攪拌隔夜且減壓濃縮。用水(400 mL)稀釋殘餘物。將沈澱物過濾,用水及tBME洗滌且在50℃下真空乾燥隔夜,得到17.50 g產物。
C11
H8
F2
IN3
O (M = 363.1 g/mol)
ESI-MS: 364 [M+H]+
Rt
(HPLC): 0.90 min (方法A)
根據上文所描述之通用程序(實例I.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
I.2 | 1.1當量NaH;0℃至RT | 382/383/384 [M+H]+ | 0.99 (B) | ||
I.3 | XII | 1.0當量NaH;0℃至RT | 382/383 [M+H]+ | 1.00 (B) |
實例 II 實例 II.1 4-(4- 乙醯基哌嗪 -1- 基 )-3- 氟苯甲腈
向0.40 g (1.95 mmol) 3-氟-4-哌嗪-1-基-苯甲腈(CAS編號182181-38-0)及0.60 ml (4.30 mmol)三乙胺於7 mL DCM中之溶液中添加0.14 mL (1.95 mmol)乙醯氯且在RT下攪拌混合物隔夜。將反應混合物用0.09 mL (1.25 mmol)三乙胺處理且在RT下攪拌2 h。將有機層用水洗滌,經PTK乾燥且減壓蒸發溶劑,得到0.5 g粗產物,其不經進一步純化即用於下一步驟中。
C13
H14
FN3
O (M = 247.3 g/mol)
ESI-MS: 248 [M+H]+
Rt
(HPLC): 0.82 min (方法B)
根據上文所描述之通用程序(實例II.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
II.2 | VI.1 | 3當量NEt3 ;1 h | 270 [M+H]+ | 0.87 (B) | |
II.3 | VII.1 | 3當量NEt3 ;1 h;用飽和KHSO4 /NaHCO3 溶液處理 | 242 [M+H]+ | 0.81 (B) | |
II.4 | VI.2 | 3當量NEt3 ;1 h;用KH2 PO4 溶液洗滌 | 242 [M+H]+ | 0.78 (B) | |
II.5 | VI.4 | 3當量NEt3 ;RT;5.5 h | 242 [M+H]+ | 0.84 (E) | |
II.6 | VI.5 | 3當量DIPEA;1.5當量乙醯氯;3 h;RT;用飽和NaHCO3 溶液/1M KHSO4 溶液處理;藉由矽膠管柱層析純化(梯度DCM/MeOH = 100:1至90:10) | 256 [M+H]+ | 0.86 (B) |
實例 III 實例 III.1 1-{4-[4-( 胺基甲基 )-2- 氟苯基 ] 哌嗪 -1- 基 } 乙 -1- 酮
將550 mg (2.22 mmol) 4-(4-乙醯基哌嗪-1-基)-3-氟苯甲腈(實例II.1)、55.0 mg雷氏鎳(Raney-Nickel)及15 mL 7 N氨於MeOH中之混合物在氫氣氛圍(50 psi)下於50℃下攪拌隔夜,過濾且真空濃縮,得到0.51 g產物。
C13
H18
FN3
O (M = 251.3 g/mol)
ESI-MS: 252 [M+H]+
Rt
(HPLC): 0.68 min (方法A)
根據上文所描述之通用程序(實例III.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
III.2 | IV.1 | 252 [M+H]+ | 0.69 (A) | ||
III.3 | V.1 | 3 h | 229 [M+H-NH3 ]+ | 0.65 (A) | |
III.4 | II.2 | 3 h | 257 [M+H-NH3 ]+ | 0.72 (A) | |
III.5 | 40℃;48 h | 217 [M+H-NH3 ]+ | 0.45 (E) | ||
III.6 | II.3 | 3.5 h | 283 [M+H-NH3 ]+ | 0.56 (B) | |
III.7 | V.4 | 用含HCl之1,4-二噁烷使產物沈澱 | 262 [M+H]+ | 0.69 (A) | |
III.8 | IX.1 | 40℃;藉由HPLC純化 | 218 [M+H-NH3 ]+ | 0.61 (A) | |
III.9 | IX.2 | 40℃;藉由HPLC純化 | 218 [M+H-NH3 ]+ | 0.63 (A) | |
III.10 | II.4 | RT;20 h | 229 [M-NH3 ]+ | 0.58 (B) | |
III.11 | X | 262 [M+H]+ | 0.67 (B) | ||
III.12 | IV.2 | 1 d | 302 [M+H]+ | 0.68 (B) | |
III.13 | V.7 | 248 [M+H]+ | 0.21 (B) | ||
III.14 | V.8 | 247 [M+H-NH3 ]+ | 0.68 (A) | ||
III.15 | II.5 | 229 [M+H-NH3 ]+ | 0.58 (E) | ||
III.16 | II.6 | 50 mg催化劑;20 mL 7M NH3 /MeOH;藉由HPLC純化 | 260 [M+H-NH3 ]+ | 0.67 (B) | |
III.17 | X.3 | 275 [M+H]+ | 0.63 (A) | ||
III.18 | X.4 | 275 [M+H]+ | 0.66 (A) | ||
III.19 | X.5 | 260 [M+H]+ | 0.71 (A) | ||
III.20 | X.6 | 260 [M+H]+ | 0.72 (A) | ||
III.21 | X.8 | 264 [M+H]+ | 0.70 (A) |
實例 IV 實例 IV.1 4-(4- 乙醯基哌嗪 -1- 基 )-2- 氟苯甲腈
將0.50 g (2.50 mmol) 4-溴-2-氟苯甲腈(CAS-No.105942-08-3),、0.32 g (2.50 mmol) 1-(哌嗪-1-基)乙-1-酮(CAS No.13889-98-0)、1.63 g (5.00 mmol)碳酸銫及0.05 g (0.06 mmol) XPhos Pd G3 (CAS編號1445085-55-1)於2 mL 1,4-二噁烷中之混合物在80℃下攪拌隔夜。用水稀釋該混合物。將剩餘固體過濾,用水洗滌且在空氣氛圍下乾燥,得到0.57 g產物。
C13
H14
FN3
O (M = 247.3 g/mol)
ESI-MS: 248 [M+H]+
Rt
(HPLC): 0.79 min (方法A)
根據上文所描述之通用程序(實例IV.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
IV.2 | 3 h;處理:用DCM萃取;經由用DIPE結晶來純化 | 298 [M+H]+ | 0.88 (B) |
實例 V 實例 V.1 4-{6- 甲基 -7- 側氧基 -2,6- 二氮雜螺 [3.4] 辛 -2- 基 } 苯甲腈
使用790 mg (5.62 mmol) K2
CO3
處理用1.6 mL DMSO稀釋之222 mg (1.81 mmol) 4-氟苯甲腈(CAS編號1194-02-1)及320 mg (1.81 mmol) 6-甲基-2,6-二氮雜螺[3.4]辛-7-酮鹽酸鹽(CAS編號2097951-61-4)且在120℃下攪拌3 h並在RT下攪拌隔夜。使反應混合物冷卻且用水稀釋。將沈澱物過濾,用水洗滌且在50℃下真空乾燥,得到340 mg產物。
C14
H15
N3
O (M = 241.3 g/mol)
ESI-MS: 242 [M+H]+
Rt
(HPLC): 0.79 min (方法B)
根據上文所描述之通用程序(實例V.1)製備以下化合物:
Ex. | 起始物質 | 結構 | |
V.2 | |||
V.3 | |||
V.4 | |||
V.5 | |||
V.6 | |||
V.7 | |||
V.8 | |||
V.9 | |||
V.10 | |||
V.11 | |||
V.12 | |||
V.13 | |||
V.14 | |||
V.15 | |||
Ex. | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
V.2 | 3.1當量K2 CO3 ,2 h | 328 [M+H]+ | 1.11 (B) |
V.3 | 2.1當量K2 CO3 ;2 h | 300 [M+H]+ | 1.06 (B) |
V.4 | 1.5當量K2 CO3 ;2.5 h;處理:用EtOAc萃取 | 258 [M+H]+ | 0.87 (B) |
V.5 | 1.65當量氟化物;隔夜 | 300 [M+H]+ | 1.04 (B) |
V.6 | 2.1當量K2 CO3 ;隔夜;處理:用EtOAc萃取 | 316 [M+H]+ | 0.88 (A) |
V.7 | 80℃;用水/EtOAc萃取;藉由HPLC純化 | 244 [M+H]+ | 0.62 min (B) |
V.8 | ACN;50℃;1.5 h;處理:過濾及濃縮 | 260 [M+H]+ | 0.87 (B) |
V.9 | 1.5當量K2 CO3 | 300 [M+H]+ | 1.02 (B) |
V.10 | 2.1當量K2 CO3 | 314 [M+H]+ | 1.12 (B) |
V.11 | DIPEA;50℃;1.5 h | 329 [M+H]+ | 1.04 (B) |
V.12 | DIPEA;60℃;1.5 h | 329 [M+H]+ | 1.02 (B) |
V.13 | 3當量K3 PO4 ;NMP;110℃;8 h;處理:用水/EE萃取;藉由HPLC純化 | 314 [M+H]+ | 1.08 (B) |
V.14 | 3當量K3 PO4 ;NMP;110℃;8 h;處理:用水/EE萃取;藉由HPLC純化 | 314 [M+H]+ | 1.07 (B) |
V.15 | 3當量K2 CO3 ;處理:過濾;濃縮;用DCM萃取 | 260 [M+H]+ | 1.06 (A) |
實例 VI 實例 VI.1 4-{2,7- 二氮雜螺 [3.5] 壬 -2- 基 } 苯甲腈 ; 三氟乙酸
用5 mL DCM稀釋255 mg (0.78 mmol)2-(4-氰基苯基)-2,7-二氮雜螺[3.5]壬烷-7-甲酸第三丁酯(實例V.2)且添加300 µL (3.89 mmol) TFA。將反應混合物在RT下攪拌2 h且減壓濃縮,得到0.26 g產物。
C14
H17
N3
*C2
HF3
O2
(M = 341.3 g/mol)
ESI-MS: 228 [M+H]+
Rt
(HPLC): 0.69 min (方法B)
根據上文所描述之通用程序(實例VI.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
VI.2 | V.5 | 4當量TFA | 200 [M+H]+ | 0.62 (B) | |
VI.3 | V.6 | 8當量TFA;隔夜 | 216 [M+H]+ | 0.84 (A) | |
VI.4 | V.9 | 隔夜 | 200 [M+H]+ | 0.78 (A) | |
VI.5 | V.10 | 攪拌1.5 h | 214 [M+H]+ | 0.70 (B) | |
VI.6 | V.11 | 4h | 229 [M+H]+ | 0.75 (A) | |
VI.7 | V.12 | 處理:添加4M NaOH;用DCM萃取;經MgSO4 乾燥;過濾;蒸發 | 229 [M+H]+ | 0.71 (A) | |
VI.8 | V.13 | 隔夜 | 214 [M+H]+ | 0.81 (A) | |
VI.9 | V.14 | 隔夜 | 214 [M+H]+ | 0.80 (A) |
實例 VII
實例VII.14-{2,6- 二氮雜螺 [3.3] 庚 -2- 基 } 苯甲腈
用1.14 g (6.01 mmol)對甲苯磺酸單水合物處理0.90 g (3.01 mmol) 6-(4-氰基苯基)-2,6-二氮雜螺[3.3]庚烷-2-甲酸第三丁酯(實例V.3)於8 mL ACN中之溶液且在RT下攪拌24 h。反應混合物用DCM稀釋且用飽和NaHCO3
溶液萃取。合併之有機層經MgSO4
乾燥且減壓濃縮,得到0.6 g產物。
C12
H13
N3
(M = 199.3 g/mol)
ESI-MS: 200 [M+H]+
Rt
(HPLC): 0.62 min (方法B)
根據上文所描述之通用程序(實例VII.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
VII.2 | V.15 | 218 [M+H]+ | 0.83 (A) |
實例 VIII N-[(4- 溴苯基 ) 甲基 ]-6-{[6-( 三氟甲基 ) 吡啶 -3- 基 ] 甲氧基 } 嗒 𠯤 -3- 胺
將含1000 mg (2.62 mmol) 3-碘-6-{[6-(三氟甲基)吡啶-3-基]甲氧基}嗒𠯤(實例I.2)、586 mg (3.15 mmol) 4-溴苯甲胺、50 mg (0.26 mmol)碘化銅、88 mg (0.52 mmol) 2-(2-甲基-1-側氧基丙基)環己酮及2.56 g (7.87 mmol)碳酸銫之10 mL DMF在60℃下攪拌隔夜。藉由HPLC純化反應混合物,得到850 mg產物。
C18
H14
BrF3
N4
O
(M = 439.2 g/mol)
ESI-MS: 439/441 [M+H]+
Rt (HPLC): 1.08 min (方法A)
實例 IX 實例 IX.1 5-(4- 乙醯基哌嗪 -1- 基 ) 吡啶 -2- 甲腈
將250 mg (2.05 mmol) 5-氟吡啶-2-甲腈(CAS編號327056-62-2)、310 mg (2.46 mmol) 1-乙醯基哌嗪(CAS編號13889-98-0)及700 µL (4.10 mmol) DIPEA於3 mL DMSO中之混合物在80℃下攪拌45 min,且用半濃縮NaCl/溶液淬滅。用EtOAc萃取水相。合併之有機相經PTK乾燥且真空濃縮,得到0.57 g產物。
C12
H14
N4
O (M = 230.3 g/mol)
ESI-MS: 231 [M+H]+
Rt
(HPLC): 0.67 min (方法A)
實例 X 實例 X.1 4-(4- 乙醯基 -3,3- 二甲基哌嗪 -1- 基 ) 苯甲腈
將800 mg (1.21 mmol) 4-(3,3-二甲基哌嗪-1-基)苯甲腈三氟乙酸(實例VI.3)溶解於3 mL吡啶中且添加2.00 mL (21.2 mmol)乙酸酐。使反應混合物回流隔夜且減壓蒸發。將殘餘物溶解於飽和NaHCO3
溶液中且用EtOAc萃取。將有機層乾燥,真空濃縮且藉由管柱層析(矽膠;梯度:DCM/MeOH = 98:2至9:1)純化,獲得產物。
C15
H19
N3
O (M = 257.3 g/mol)
ESI-MS: 258 [M+H]+
Rt
(HPLC): 0.85 min (方法A)
根據上文所描述之通用程序(實例X.1)製備以下化合物:
Ex. | 起始物質 | 結構 | 反應條件 | ESI-MS | HPLC滯留時間(方法) [min] |
X.2 | 1.1當量乙酸酐;DCM | 283 [M+H]+ | 0.74 (A) | ||
X.3 | VI.6 | 2.7當量乙酸酐;RT;隔夜;蒸發 | 271 [M+H]+ | 0.76 (A) | |
X.4 | VI.7 | 1.8當量乙酸酐;RT;隔夜;蒸發 | 271 [M+H]+ | 0.91 (A) | |
X.5 | VI.8 | 1.2當量乙酸酐;3當量TEA;DCM;RT;隔夜;處理:用水、1M檸檬酸及稀釋氨水萃取;蒸發 | 256 [M+H]+ | 0.81 (A) | |
X.6 | VI.9 | 1.1當量乙酸酐;3當量TEA;DCM;RT;隔夜;處理:用水、1M檸檬酸及稀釋氨水萃取;蒸發 | 256 [M+H]+ | 0.80 (A) | |
X.8 | VII.2 | 1.1當量乙酸酐;DCM;3.5 h;RT;處理:藉由HPLC純化 | 260 [M+H]+ | 0.96 (B) |
實例 XI 6-( 二氟甲基 )-5- 氟吡啶 -3- 甲酸甲酯
用154.8 mg (0.28 mmol) 1,1`-雙(二苯基膦基)二茂鐵、63.5 mg (0.28 mmol)乙酸鈀(II)及1.5 mL (10.79 mmol) TEA處理含800 mg (3.54 mmol) 5-溴-2-(二氟甲基)-3-氟吡啶[由市售的5-溴-3-氟吡啶-2-甲醛(1當量) CAS編號669066-93-7,經由與含脫氧加氟物(2當量)之DCM反應隔夜來製備]之40 mL MeOH。將反應混合物在一氧化碳氛圍(5巴)下在50℃下攪拌15 h。過濾反應混合物且真空蒸發濾液,得到產物。藉由管柱層析(矽膠;梯度:Cy/EE = 100:0至60:40)純化殘餘物,得到460 mg產物。
C8
H6
F3
NO2
(M = 205.1 g/mol)
ESI-MS: 206 [M+H]+
Rt
(HPLC): 0.88 min (方法B)
實例 XII [6-( 二氟甲基 )-5- 氟吡啶 -3- 基 ] 甲醇
在氮氣氛圍下用溶解於10 mL THF中之460 mg (2.42 mmol) 6-(二氟甲基)-5-氟吡啶-3-甲酸甲酯(實例XI)處理含98 mg (4.49 mmol)硼氫化鋰之10 mL THF。添加0.2 mL MeOH且將反應混合物在50℃下攪拌2 h。用5 mL 1 M鹽酸稀釋反應混合物且在氣體析出後蒸發THF。用4M NaOH使殘餘物鹼化且用DCM萃取水溶液。真空蒸發有機相以得到產物。藉由管柱層析(矽膠;梯度:Cy/EE = 80:20至20:80)純化殘餘物,得到290 mg產物。
C7
H6
F3
NO (M = 177.1 g/mol)
ESI-MS: 178 [M+H]+
Rt
(HPLC): 0.64 min (方法B)
實例 XIII 1-[(3aR,8aS)- 十氫吡咯并 [3,4-d] 氮呯 -6- 基 ] 乙 -1- 酮鹽酸鹽
用30 mL 1,4-二噁烷稀釋2.64 g (9.3 mmol) (3aR,8aS)-6-乙醯基-十氫吡咯并[3,4-d]氮呯-2-甲酸第三丁酯(實例X.2),添加含9.3 mL (37.4 mmol) 4 M氯化氫之1,4-二噁烷且在RT下攪拌反應混合物4 h。向反應混合物中添加含1當量4 M氯化氫之1,4-二噁烷且在RT下攪拌隔夜。真空蒸發混合物,用二乙醚處理殘餘物且過濾沈澱物。將濾餅用MeOH稀釋且蒸發,得到產物。
C10
H18
N2
O*HCl
(M = 182.3 g/mol)
ESI-MS: 183 [M+H]+
Rt
(HPLC): 0.50 min (方法A)
實例 XIV N-(4-((3aR,3bS,6aR,6bS)- 八氫環丁 [1,2-c:3,4-c'] 二吡咯 -2(1H)- 基 ) 苯甲基 )-6-((6-( 三氟甲基 ) 吡啶 -3- 基 ) 甲氧基 ) 嗒 𠯤 -3- 胺
在氬氣氛圍下將59.7 mg (0.27 mmol) (3aR,3bR,6aS,6bS)-十氫環丁[1,2-c:3,4-c']二吡咯、120.0 mg (0.27 mmol ) N-[(4-溴苯基)甲基]-6-{[6-(三氟甲基)吡啶-3-基]甲氧基}嗒𠯤-3-胺(實例VIII)、3.07 mg (0.01 mmol)乙酸鈀(II)、6.5 mg (0.01 mmol) X-Phos及89.0 mg (0.27 mmol)碳酸銫溶解於2.00 mL甲苯及0.50 mL第三丁醇中。將溶液脫氣幾次。在80℃下攪拌反應溶液隔夜。將反應混合物用水稀釋且用EE萃取。有機層經MgSO4
乾燥,經木炭過濾且蒸發。藉由HPLC純化殘餘物,得到15 mg產物。
C28
H31
F3
N6
O2
(M = 496.5 g/mol)
ESI-MS: 497 [M+H]+
Rt
(HPLC): 0.98 min (方法A)
製備最終化合物 實例 1.1
1-(6-(4-(((6-((6-(三氟甲基)吡啶-3-基)甲氧基)嗒𠯤-3-基)胺基)甲基)苯基)-2,6-二氮雜螺[3.3]庚-2-基)乙-1-酮
向163 mg (0.43 mmol) 3-碘-6-((6-(三氟甲基)吡啶-3-基)甲氧基)嗒𠯤(實例I.2)及150 mg (0.43 mmol) 1-(6-(4-(胺基甲基)苯基)-2,6-二氮雜螺[3.3]庚-2-基)乙-1-酮(實例III.6)於2 mL二甲基乙醯胺中之溶液中添加418 mg (1.28 mmol)碳酸銫、8.1 mg (0.04 mmol)碘化銅(I)及14.4 mg (0.09 mmol) 2-(2-甲基-1-側氧基丙基)環己酮,且在50℃下攪拌混合物隔夜。用乙腈稀釋混合物,過濾且藉由HPLC純化濾過物,得到43 mg所需產物。
C25
H25
F3
N6
O2
(M = 498.5 g/mol)
ESI-MS: 499 [M+H]+
Rt
(HPLC): 0.93 min (方法A)1
H NMR (400 MHz, DMSO-d6
) δ 8.84 (d,J
=1.52 Hz, 1H), 8.13 (dd,J
=1.39, 8.11 Hz, 1H), 7.92 (d,J
=8.11 Hz, 1H), 7.16 (d,J
=8.49 Hz, 2H), 6.89-7.03 (m, 2H), 6.84 (t,J
=5.64 Hz, 1H), 6.40 (d,J
=8.49 Hz, 2H), 5.48 (s, 2H), 4.33 (d,J
=5.58 Hz, 2H), 4.27 (s, 2H), 3.99 (s, 2H), 3.89 (s, 4H), 1.74 (s, 3H)
根據上文所描述之通用程序(實例1.1)製備以下化合物:
Ex. | 起始物質 | 結構 | |
1.2 | I.1 | III.6 | |
1.3 | I.1 | III.1 | |
1.4 | I.1 | III.2 | |
1.5 | I.1 | III.3 | |
1.6 | I.1 | III.4 | |
1.7 | I.1 | III.11 | |
Ex. | 反應條件 | ESI-MS | HPLC 滯留時間 ( 方法 ) [min] |
1.2 | 直接藉由HPLC純化 | 481 [M+H]+ | 0.89 (A) |
1.3 | 直接藉由HPLC純化 | 487 [M+H]+ | 0.69 (C) |
1.4 | 直接藉由HPLC純化 | 487 [M+H]+ | 0.70 (C) |
1.5 | 1.1當量苯甲胺;40℃ | 481 [M+H]+ | 0.66 (D) |
1.6 | 1.1當量苯甲胺;40℃ | 509 [M+H]+ | 0.72 (D) |
1.7 | 直接藉由HPLC純化 | 497 [M+H]+ | 0.77 (C) |
Ex. | 1 H-NMR 資料 |
1.2 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (s, 1H), 8.05 (dd,J =1.71, 8.05 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.17 (d,J =8.36 Hz, 2H), 6.95 (q,J =9.42 Hz, 3H), 6.77-6.86 (m, 1H), 6.40 (d,J =8.36 Hz, 2H), 5.44 (s, 2H), 4.34 (d,J =5.58 Hz, 2H), 4.27 (s, 2H), 3.99 (s, 2H), 3.89 (s, 4H), 1.74 (s, 3H) |
1.3 | 1H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J=1.39 Hz, 1H), 8.05 (dd, J=1.90, 7.98 Hz, 1H), 7.71 (d, J=7.86 Hz, 1H), 6.94-7.20 (m, 7H), 5.44 (s, 2H), 4.42 (d, J=5.70 Hz, 2H), 3.55-3.63 (m, 4H), 2.88-3.00 (m, 4H), 2.03 (s, 3H) |
1.4 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (s, 1H), 8.05 (dd,J =1.52, 7.98 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.24 (t,J =8.74 Hz, 1H), 6.91-7.02 (m, 3H), 6.87 (t,J =5.58 Hz, 1H), 6.71-6.83 (m, 2H), 5.44 (s, 2H), 4.40 (d,J =5.58 Hz, 2H), 3.55 (br s, 4H), 3.06-3.20 (m, 4H), 2.03 (s, 3H) |
1.5 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (s, 1H), 8.05 (dd,J =1.27, 7.98 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.17 (d,J =8.24 Hz, 2H), 6.95 (q,J =9.42 Hz, 3H), 6.79-6.86 (m, 1H), 6.40 (d,J =8.24 Hz, 2H), 5.44 (s, 2H), 4.34 (d,J =5.58 Hz, 2H), 3.69-3.80 (m, 4H), 3.57 (s, 2H), 2.72 (s, 3H), 2.57 (s, 2H) |
1.6 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (s, 1H), 8.01-8.09 (m, 1H), 7.71 (d,J =8.11 Hz, 1H), 7.16 (d,J =8.24 Hz, 2H), 6.90-7.10 (m, 3H), 6.79-6.84 (m, 1H), 6.38 (d,J =8.36 Hz, 2H), 5.44 (s, 2H), 4.33 (d,J =5.58 Hz, 2H), 3.50-3.59 (m, 4H), 3.40 (td,J =5.53, 14.04 Hz, 4H), 1.99 (s, 3H), 1.58-1.80 (m, 4H) |
1.7 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (d,J =1.52 Hz, 1H), 8.05 (dd,J =1.96, 8.05 Hz, 1H), 7.69-7.74 (m, 1H), 7.18 (d,J =8.62 Hz, 2H), 6.90-7.11 (m, 3H), 6.78-6.84 (m, 1H), 6.69 (d,J =8.74 Hz, 2H), 5.44 (s, 2H), 4.33 (d,J =5.58 Hz, 2H), 3.72 (t,J =5.64 Hz, 2H), 3.33-3.36 (m, 4H), 2.01 (s, 3H), 1.38 (s, 6H) |
實例 2.1 N- 甲基 -N-[1-(4-{[(6-{[6-( 三氟甲基 ) 吡啶 -3- 基 ] 甲氧基 } 嗒 𠯤 -3- 基 ) 胺基 ] 甲基 } 苯基 ) 哌啶 -4- 基 ] 乙醯胺
50.0 mg (0.13 mmol) 3-碘-6-{[6-(三氟甲基)吡啶-3-基]甲氧基}-嗒𠯤(實例I .2)、45.20 mg (0.14 mmol) 1-{4-[4-(1-胺基環丙基)苯基]-哌嗪-1-基}乙-1-酮(實例III.7)、6.2 mg (32.8 µmol)碘化銅、13.2 mg (0.07 mmol) [(2,6-二氟苯基)胺甲醯基]甲酸(CAS編號1018295-42-5)及85.5 mg (0.39 mmol)磷酸鉀於2 mL DMSO中之混合物在80℃下攪拌1.5 h,隨後在100℃下攪拌1 h。直接藉由HPLC純化反應混合物,得到54 mg產物。
C26
H29
F3
N6
O2
(M = 514.5 g/mol)
ESI-MS: 515 [M+H]+
Rt
(HPLC): 0.60 min (方法C)1
H NMR (400 MHz, DMSO-d6
) δ 8.84 (d,J
=1.14 Hz, 1H), 8.14 (dd,J
=1.39, 8.11 Hz, 1H), 7.92 (d,J
=8.11 Hz, 1H), 7.19 (d,J
=8.24 Hz, 2H), 6.84-7.05 (m, 5H), 5.49 (s, 2H), 4.29-4.46 (m, 3H), 3.64-3.82 (m, 3H), 2.59-2.87 (m, 5H), 1.94-2.11 (m, 3H), 1.45-1.92 (m, 4H)
根據上文所描述之通用程序(實例2.1)製備以下化合物:
Ex. | 起始物質 | 結構 | |
2.2 | I.2 | III.5 | |
2.3 | I.1 | III.9 | |
2.4 | I.1 | III.8 | |
2.5 | I.2 | III.9 | |
2.6 | I.1 | III.10 | |
2.7 | I.1 | III.12 | |
2.8 | I.2 | III.13 | |
2.9 | I.2 | III.14 | |
2.10 | I.1 | III.13 | |
2.11 | I.2 | III.15 | |
2.12 | I.3 | III.5 | |
2.13 | I.2 | III.16 | |
2.14 | I.1 | III.16 | |
2.15 | I.2 | III.8 | |
2.16 | I.1 | III.17 | |
2.17 | I.2 | III.18 | |
2.18 | I.1 | III.18 | |
2.19 | I.2 | III.19 | |
2.20 | I.2 | III.20 | |
2.21 | I.2 | III.21 | |
2.22 | I.2 | III.4 | |
2.23 | I.2 | III.10 |
Ex. | 反應條件 | ESI-MS | HPLC 滯留時間 ( 方法 ) [min] |
2.2 | 1.1當量苯甲胺;0.25當量CuI;0.5當量配位體;120℃;3 h | 487 [M+H]+ | 0.79 (B) |
2.3 | 1當量碘化物;1.1當量胺;100℃;2.5 h | 470 [M+H]+ | 0.85 (A) |
2.4 | 1當量碘化物;1.1當量胺;80℃;1.5 h | 470 [M+H]+ | 0.82 (A) |
2.5 | 1當量碘化物;1.1當量胺;80℃;1.5 h;100℃;1 h | 488 [M+H]+ | 0.90 (A) |
2.6 | 1當量碘化物;1.14當量胺;80℃;直接藉由HPLC純化 | 481 [M+H]+ | 0.66 (D) |
2.7 | 1當量碘化物;1.5當量胺;隔夜;直接藉由HPLC純化 | 537 [M+H]+ | 0.84 (B) |
2.8 | 1.0當量碘化物;1.1當量苯甲胺;0.5當量CuI;0.5當量配位體;50℃;隔夜;直接藉由HPLC純化 | 501 [M+H]+ | 0.74 (D) |
2.9 | 1.0當量碘化物;1.1當量苯甲胺;0.5當量CuI;0.5當量配位體;50℃;隔夜;直接藉由HPLC純化 | 517 [M+H]+ | 0.92 (A) |
2.10 | 1當量碘;1.1當量苯甲胺;0.5當量CuI;0.5當量配位體;50℃;隔夜;直接藉由HPLC純化 | 483 [M+H]+ | 0.67 (D) |
2.11 | 0.25當量CuI;0.5當量配位體;50℃;隔夜;直接藉由HPLC純化 | 499 [M+H]+ | 0.75 (D) |
2.12 | 0.2當量CuI;3當量鹼;0.4當量配位體;70℃;3 h;直接藉由HPLC純化 | 487 [M+H]+ | 0.69 (D) |
2.13 | 0.2當量CuI;3當量鹼;0.4當量配位體;70℃隔夜;直接藉由HPLC純化 | 513 [M+H]+ | 0.77 (C) |
2.14 | 0.2當量CuI;3當量鹼;0.4當量配位體;70℃隔夜;直接藉由HPLC純化 | 495 [M+H]+ | 0.70 (C) |
2.15 | 1當量碘化物;1.1當量胺;80℃;30 min | 488 [M+H]+ | 0.88 (A) |
2.16 | 3當量鹼;0.4當量配位體;80℃;45 min;110℃;10 min;用EE萃取;藉由HPLC純化 | 510 [M+H]+ | 0.62 (D) |
2.17 | 3當量鹼;0.4當量配位體;70℃;隔夜;直接藉由HPLC純化 | 528 [M+H]+ | 0.68 (D) |
2.18 | 3當量鹼;0.4當量配位體;70℃;隔夜;RT過週末;直接藉由HPLC純化 | 510 [M+H]+ | 0.62 (D) |
2.19 | 3當量鹼;0.4當量配位體;80℃;隔夜;處理:用飽和NH4 Cl/NH3 稀釋;將沈澱物過濾且直接藉由HPLC純化 | 513 [M+H]+ | 0.96 (A) |
2.20 | 3當量鹼;0.4當量配位體;80℃;隔夜;處理:用飽和NH4 Cl/NH3 稀釋;將沈澱物過濾且直接藉由HPLC純化 | 513 [M+H]+ | 0.96 (A) |
2.21 | 3當量鹼;0.4當量配位體;80℃;隔夜;處理:用飽和NH4 Cl/NH3 稀釋;用EE萃取;藉由HPLC純化 | 517 [M+H]+ | 0.96 (A) |
2.22 | 3當量鹼;0.4當量配位體;70℃;2 h;室溫隔夜; | 527 [M+H]+ | 0.79 (C) |
2.23 | 3當量鹼;0.4當量配位體;80℃;隔夜;處理:用飽和NH4 Cl/NH3 稀釋;用EE萃取;藉由HPLC純化 | 499 [M+H]+ | 0.93 (A) |
Ex. | 1 H-NMR 資料 |
2.2 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (d,J =1.14 Hz, 1H), 8.13 (dd,J =1.39, 8.11 Hz, 1H), 7.92 (d,J =7.98 Hz, 1H), 7.22 (d,J =8.62 Hz, 2H), 6.85-7.04 (m, 5H), 5.49 (s, 2H), 4.37 (d,J =5.70 Hz, 2H), 3.48-3.64 (m, 4H), 2.98-3.16 (m, 4H), 2.03 (s, 3H) |
2.3 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (d,J =1.39 Hz, 1H), 8.13 (d,J =2.15 Hz, 1H), 8.05 (dd,J =1.90, 8.11 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.56 (dd,J =2.41, 8.74 Hz, 1H), 6.75-7.02 (m, 5H), 5.45 (s, 2H), 4.34 (d,J =5.70 Hz, 2H), 3.48-3.57 (m, 6H), 3.38-3.47 (m, 2H), 2.03 (s, 3H) |
2.4 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (d,J =1.39 Hz, 1H), 8.24 (br d,J =1.77 Hz, 1H), 8.05 (dd,J =1.96, 8.05 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.33 (dd,J =2.85, 8.68 Hz, 1H), 7.21 (d,J =8.62 Hz, 1H), 6.90-7.12 (m, 4H), 5.43 (s, 2H), 4.48 (d,J =5.70 Hz, 2H), 3.57 (br d,J =3.80 Hz, 4H), 3.05-3.22 (m, 4H), 2.04 (s, 3H) |
2.5 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.85 (d,J =1.27 Hz, 1H), 8.08-8.17 (m, 2H), 7.92 (d,J =8.11 Hz, 1H), 7.56 (dd,J =2.41, 8.74 Hz, 1H), 6.96-7.04 (m, 1H), 6.85-6.96 (m, 2H), 6.82 (d,J =8.74 Hz, 1H), 5.49 (s, 2H), 4.34 (d,J =5.70 Hz, 2H), 3.35-3.60 (m, 8H), 2.03 (s, 3H) |
2.6 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (s, 1H), 8.05 (d,J =8.11 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.16 (dd,J =2.41, 8.62 Hz, 2H), 6.88-7.02 (m, 3H), 6.74-6.86 (m, 1H), 6.57 (d,J =7.86 Hz, 2H), 5.45 (s, 2H), 4.43-4.79 (m, 2H), 4.33 (t,J =5.51 Hz, 2H), 3.44-3.66 (m, 2H), 2.85-3.28 (m, 2H), 1.70-2.06 (m, 5H) |
2.7 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (d,J =1.52 Hz, 1H), 8.05 (dd,J =1.96, 8.05 Hz, 1H), 7.71 (d,J =8.11 Hz, 1H), 7.43 (d,J =8.24 Hz, 1H), 7.14-7.24 (m, 2H), 6.91-7.04 (m, 4H), 5.44 (s, 2H), 4.56 (br d,J =5.32 Hz, 2H), 3.57 (br d,J =3.55 Hz, 4H), 3.11-3.26 (m, 4H), 2.04 (s, 3H) |
2.8 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (d,J =1.01 Hz, 1H), 8.14 (dd,J =1.46, 8.05 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.20 (d,J =8.62 Hz, 2H), 6.92-7.03 (m, 2H), 6.84-6.92 (m, 3H), 5.49 (s, 2H), 4.51-4.61 (m, 2H), 4.46 (t,J =6.02 Hz, 2H), 4.36 (d,J =5.70 Hz, 2H), 3.44 (quin,J =6.27 Hz, 1H), 3.07-3.17 (m, 4H), 2.36-2.44 (m, 4H) |
2.9 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (d,J =1.27 Hz, 1H), 8.13 (dd, J=1.39, 8.11 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 6.91-7.05 (m, 5H), 6.50 (dd,J =8.49, 9.38 Hz, 1H), 5.48 (s, 2H), 4.35 (d,J =5.70 Hz, 2H), 4.26 (s, 2H), 3.98 (d,J =1.65 Hz, 6H), 1.74 (s, 3H) |
2.10 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (d,J =1.39 Hz, 1H), 8.05 (dd,J =1.90, 7.98 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.20 (d,J =8.62 Hz, 2H), 6.83-7.11 (m, 6H), 5.44 (s, 2H), 4.52-4.59 (m, 2H), 4.46 (t,J =6.08 Hz, 2H), 4.36 (d,J =5.58 Hz, 2H), 3.38-3.49 (m, 1H), 3.04-3.18 (m, 4H), 2.34-2.44 (m, 4H) |
2.11 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (s, 1H), 8.13 (dd,J =1.33, 8.05 Hz, 1H), 7.99 (d,J =3.93 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.14 (d,J =8.49 Hz, 2H), 6.89-7.02 (m, 2H), 6.81 (t,J =5.58 Hz, 1H), 6.50 (d,J =8.62 Hz, 2H), 5.49 (s, 2H), 4.32 (d, J=5.58 Hz, 2H), 3.52 (d,J =9.38 Hz, 2H), 3.14 (br d,J =8.62 Hz, 2H), 2.42 (td,J =2.11, 3.77 Hz, 1H), 1.70-1.80 (m, 5H) |
2.12 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.62 (s, 1H), 8.01 (d,J =11.03 Hz, 1H), 7.10-7.29 (m, 3H), 6.95-7.04 (m, 2H), 6.85-6.95 (m, 3H), 5.46 (s, 2H), 4.37 (d,J =5.70 Hz, 2H), 3.51-3.60 (m, 4H), 2.98-3.16 (m, 4H), 2.03 (s, 3H) |
2.13 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (d,J =1.27 Hz, 1H), 8.13 (dd,J =1.46, 8.05 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.16 (d,J =8.62 Hz, 2H), 6.89-7.03 (m, 2H), 6.81 (t,J =5.64 Hz, 1H), 6.50 (d,J =8.62 Hz, 2H), 5.49 (s, 2H), 4.33 (d,J =5.58 Hz, 2H), 3.73 (dd,J =7.67, 10.58 Hz, 1H), 3.57 (dd,J =7.73, 12.17 Hz, 1H), 3.33-3.48 (m, 3H), 3.19-3.26 (m, 1H), 2.90-3.18 (m, 4H), 1.93 (s, 3H) |
2.14 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.76 (d,J =1.39 Hz, 1H), 8.05 (dd,J =1.90, 7.98 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.16 (d,J =8.49 Hz, 2H), 6.89-7.11 (m, 3H), 6.77-6.84 (m, 1H), 6.50 (d,J =8.62 Hz, 2H), 5.44 (s, 2H), 4.33 (d,J =5.58 Hz, 2H), 3.73 (dd,J =7.60, 10.65 Hz, 1H), 3.57 (dd,J =7.73, 12.17 Hz, 1H), 3.32-3.48 (m, 3H), 3.22 (dd,J =4.69, 12.17 Hz, 1H), 2.90-3.19 (m, 4H), 1.93 (s, 3H) |
2.15 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (d,J =1.27 Hz, 1H), 8.24 (d,J =2.66 Hz, 1H), 8.13 (dd,J =1.52, 8.11 Hz, 1H), 7.92 (d,J =7.98 Hz, 1H), 7.32 (dd,J =2.92, 8.62 Hz, 1H), 7.21 (d,J =8.62 Hz, 1H), 6.98-7.08 (m, 3H), 5.48 (s, 2H), 4.48 (d,J =5.70 Hz, 2H), 3.57 (br d,J =3.55 Hz, 4H), 3.06-3.24 (m, 4H), 2.04 (s, 3H) |
2.16 | 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 8.76 (d,J =1.39 Hz, 1H), 8.05 (dd,J =7.98, 2.03 Hz, 1H), 7.75 (d,J =2.79 Hz, 1H), 7.71 (d,J =7.98 Hz, 1H), 7.16 (d,J =8.36 Hz, 1H), 7.09 (s, 1H), 7.00 (d,J =4.31 Hz, 2H), 6.92-6.98 (m, 2H), 6.71-6.89 (m, 1H), 5.44 (s, 2H), 4.44 (d,J =5.83 Hz, 2H), 3.62 (d,J =1.77 Hz, 4H), 2.67 (t,J =1.84 Hz, 1 H), 2.33 (t,J =1.84 Hz, 1 H), 2.00 (s, 3 H), 1.70-1.83 (m, 2 H), 1.56-1.70 (m, 2H), 1.24 (s, 1H) |
2.17 | 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 8.85 (d,J =1.27 Hz, 1H), 8.14 (dd,J =8.05, 1.46 Hz, 1H), 8.05 (d,J =1.90 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.52 (d,J =2.28 Hz, 1H), 7.50 (d,J =2.28 Hz, 1H), 6.97-7.02 (m, 1H), 6.91-6.95 (m, 1 H), 6.34 (d,J =8.49 Hz, 1H), 5.49 (s, 2H), 4.31 (d,J =5.58 Hz, 2H), 3.66 (d,J =1.27 Hz, 4H), 3.40 (dt,J =14.54, 5.66 Hz, 4H), 2.07 (s, 1H), 1.99 (s, 3H), 1.70-1.77 (m, 2H), 1.26 (s, 1H) |
2.18 | 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 8.76 (d,J =1.52 Hz, 1H), 8.01 - 8.09 (m, 1 H), 7.71 (d,J =8.11 Hz, 1H), 7.51 (dd,J =8.49, 2.41 Hz, 1H), 7.09 (s, 1H), 6.90-7.01 (m, 1 H), 6.87 (t,J =5.64 Hz, 1H), 6.82 (s, 1 H), 6.34 (d,J =8.36 Hz, 1H), 5.45 (s, 2H), 4.32 (d,J =5.70 Hz, 2H), 3.66 (d,J =1.27 Hz, 4H), 3.40 (dt,J =14.76, 5.54 Hz, 4H), 2.5 (m, 1H), 1.99 (s, 3H), 1.71-1.77 (m, 2 H), 1.61-1.68 (m, 2H) |
2.19 | 1H NMR (400 MHz, DMSO-d6 ) δ ppm 8.85 (d,J =1.39 Hz, 1H), 8.14 (dd,J =8.05, 1.46 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.19 (d,J =8.62 Hz, 2H), 6.98 (q,J =9.38 Hz, 2H), 6.85-6.88 (m, 2H), 6.84 (s, 1H), 5.49 (s, 2H), 4.35 (d,J =5.58 Hz, 2H), 4.27 (br d,J =5.20 Hz, 2H), 3.80-3.97 (m, 1H), 3.39 (br d,J =11.79 Hz, 2H), 2.84 (br d,J =12.80 Hz, 1H), 1.96 (s, 3H), 1.84-1.91 (m, 2H), 1.68-1.81 (m, 1H), 1.48-1.64 (m, 1H) |
2.20 | 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 8.85 (d,J =1.27 Hz, 1H), 8.14 (dd,J =8.05, 1.46 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.17 (d,J =8.74 Hz, 2H), 6.90-7.02 (m, 2H), 6.82 (br d,J =3.55 Hz, 1H), 6.54-6.70 (m, 2H), 5.49 (s, 2H), 4.60 (br s, 1H), 4.32 (d,J =5.58 Hz, 2H), 4.05-4.23 (m, 2H), 3.57 - 3.71 (m, 1H), 3.52 (br d,J =10.14 Hz, 1H), 3.42 (br s, 2H), 2.01 (s, 2H), 1.90 (s, 3H), 1.67-1.86 (m, 1H) |
2.21 | 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 8.85 (d,J =1.39 Hz, 1H), 8.14 (dd,J =8.11, 1.52 Hz, 1H), 7.92 (d,J =7.98 Hz, 1H), 7.20 (t,J =8.43 Hz, 1H), 6.90-7.03 (m, 2 H), 6.83 (t,J =5.58 Hz, 1H), 6.12-6.37 (m, 2H), 5.49 (s, 2H), 4.37 (d,J =5.45 Hz, 2H), 4.27 (s, 2H), 3.99 (s, 2H), 3.92 (s, 4H), 1.74 (s, 3H) |
2.22 | 1 H NMR (400 MHz, DMSO-d6 ) δ 8.84 (d,J =1.39 Hz, 1H), 8.14 (dd,J =1.52, 8.11 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.16 (d,J =8.49 Hz, 2H), 6.90-7.05 (m, 2H), 6.83 (t,J =5.70 Hz, 1H), 6.38 (d,J =8.49 Hz, 2H), 5.49 (s, 2H), 4.33 (d,J =5.58 Hz, 2H), 3.51-3.59 (m, 4H), 3.37-3.45 (m, 4H), 1.99 (s, 3H), 1.60-1.78 (m, 4H) |
2.23 | 1 H NMR (400 MHz, DMSO-d6 ) δ ppm 8.85 (s, 1H), 8.14 (d,J =8.11 Hz, 1H), 7.92 (d,J =8.11 Hz, 1H), 7.16 (dd,J =8.62, 2.66 Hz, 1H), 6.97 - 7.05 (m, 1H), 6.95 (d,J =5.45 Hz, 1H), 6.92 (d,J =5.45 Hz, 1H), 6.77 - 6.89 (m, 1H), 6.56 (d,J =7.98 Hz, 2H), 5.49 (s, 2H), 4.74 (s, 1H), 4.58 (br d,J =8.74 Hz, 1H), 4.47 (s, 1H), 4.32 (t,J =5.51 Hz, 2H), 3.58 (dd,J =9.00, 1.77 Hz, 1H), 3.48-3.55 (m, 1H), 3.34 (d,J =9.89 Hz, 1H), 2.91 (d,J =8.87 Hz, 1H), 1.98 (s, 2H), 1.90-1.95 (m, 1H) 1.80-1.89 (m, 1H) |
實例 3 1-[4-(4-{[(6-{[6-( 二氟甲基 ) 吡啶 -3- 基 ] 甲氧基 } 嗒 𠯤 -3- 基 ) 胺基 ] 甲基 }- 苯基 ) 哌嗪 -1- 基 ] 乙 -1- 酮
將80.0 mg (0.22 mmol) 3-{[6-(二氟甲基)吡啶-3-基]甲氧基}-6-碘-嗒𠯤(實例I.1)、61.7 mg (0.26 mmol) 1-{4-[4-(胺基甲基)苯基]哌嗪-1-基}乙-1-酮(實例III.5)、260 µL (0.66 mmol)第三戊醇鈉(2.5 mol/L於甲基-THF中)及2.0 mg (2.20 µmol) JOSIPHOS SL-J009-1 Pd G3 (MDL編號MFCD27978424)於0.4 mL第三戊醇中之混合物在35℃下攪拌隔夜。將反應混合物用ACN及DMF稀釋,過濾且藉由製備型HPLC純化,產生12 mg產物。
C24
H26
F2
N6
O2
(M = 468.5 g/mol)
ESI-MS: 469 [M+H]+
Rt
(HPLC): 0.88 min (方法A)1
H NMR (400 MHz, DMSO-d6
) δ 8.76 (d,J
=1.39 Hz, 1H), 8.05 (dd,J
=1.90, 7.98 Hz, 1H), 7.71 (d,J
=7.98 Hz, 1H), 7.22 (d,J
=8.62 Hz, 2H), 6.97-7.12 (m, 1H), 6.83-6.97 (m, 5H), 5.44 (s, 2H), 4.37 (d,J
=5.58 Hz, 2H), 3.50-3.60 (m, 4H), 3.00-3.20 (m, 4H), 2.03 (s, 3H)
實例 4 1-[(3aR,8aS)-2-(4-{[(6-{[6-( 三氟甲基 ) 吡啶 -3- 基 ] 甲氧基 } 嗒 𠯤 -3- 基 ) 胺基 ] 甲基 } 苯基 )- 十氫吡咯并 [3,4-d] 氮呯 -6- 基 ] 乙 -1- 酮
在氬氣氛圍下將59.7 mg (0.27 mmol) 1-[(3aR,8aS)-十氫吡咯并[3,4-d]氮呯-6-基]乙-1-酮鹽酸鹽(實例XIII)、100.0 mg (0.23 mmol) N-[(4-溴苯基)甲基]-6-{[6-(三氟甲基)吡啶-3-基]甲氧基}嗒𠯤-3-胺(實例VIII)、17.7 mg (0.02 mmol)第2代Ruphos預催化劑及48.1 mg (0.50 mmol)第三丁醇鈉溶解於1.00 mL甲基-THF中。將溶液脫氣幾次。在80℃下攪拌反應溶液2 h。隨後再添加481 mg (0.50 mmol)第三丁醇鈉且在100℃下攪拌反應溶液隔夜。將反應溶液過濾且藉由HPLC純化,得到14 mg產物。
C28
H31
F3
N6
O2
(M = 540.6 g/mol)
ESI-MS: 541 [M+H]+
Rt
(HPLC): 0.81 min (方法F)1
H NMR (400 MHz, DMSO-d6
) δ 8.84 (d,J
=1.27 Hz, 1H), 8.13 (dd,J
=1.46, 8.05 Hz, 1H), 7.92 (d,J
=7.98 Hz, 1H), 7.14 (d,J
=8.49 Hz, 2H), 6.90-7.05 (m, 2H), 6.79 (t,J
=5.64 Hz, 1H), 6.47 (d,J
=8.62 Hz, 2H), 5.49 (s, 2H), 4.31 (d,J
=5.58 Hz, 2H), 3.57-3.80 (m, 2H), 3.33-3.46 (m, 4H), 3.20-3.30 (m, 2H), 2.93 (td,J
=6.23, 9.35 Hz, 2H), 2.00 (s, 3H), 1.53-1.89 (m, 4H)
實例 5 1-((3aR,3bS,6aR,6bS)-5-(4-(((6-((6-( 三氟甲基 ) 吡啶 -3- 基 ) 甲氧基 ) 嗒 𠯤 -3- 基 ) 胺基 ) 甲基 ) 苯基 ) 八氫環丁 [1,2-c:3,4-c'] 二吡咯 -2(1H)- 基 ) 乙 -1- 酮
將15 mg (0.03 mmol) N-(4-((3aR,3bS,6aR,6bS)-八氫環丁[1,2-c:3,4-c']二吡咯-2(1H)-基)苯甲基)-6-((6-(三氟甲基)吡啶-3-基)甲氧基)嗒𠯤-3-胺(實例XIV)溶解於0.5 mL DCM中且添加2.86 µL mL (0.03 mmol)乙酸酐。在RT下攪拌反應混合物1 h。反應溶液用0.5 mL MeOH稀釋且藉由HPLC純化,得到7 mg產物。
C28
H29
F3
N6
O2
(M = 538.564 g/mol)
ESI-MS: 539 [M+H]+
Rt
(HPLC): 0.99 min (方法A)1
H NMR (400 MHz, DMSO-d6
) δ 9.12 (s, 1H), 8.89 (d,J
=1.14 Hz, 1H), 8.19 (dd,J
=1.52, 8.11 Hz, 1H), 7.94 (d,J
=8.24 Hz, 1H), 7.85 (d,J
=9.50 Hz, 1H), 7.41 (d,J
=9.38 Hz, 1H), 7.08 (d,J
=8.49 Hz, 2H), 6.65 (d,J
=8.62 Hz, 2H), 5.63 (s, 2H), 5.06 (s, 2H), 3.79 (d,J
=12.17 Hz, 1H), 3.66 (d,J
=11.15 Hz, 1H), 3.54 (dd,J
=1.90, 9.89 Hz, 2H), 3.35 (br dd,J
=6.78, 11.22 Hz, 2H), 3.06 (dd,J
=6.84, 12.29 Hz, 1H), 2.82 (br dd,J
=6.97, 9.51 Hz, 2H), 2.55-2.64 (m, 1H), 2.44-2.49 (m, 2H), 2.02-2.06 (m, 3H)
分析型 HPLC 方法 方法 A
分析型管柱:XBridge C18 (Waters) 2.5 µm;3.0×30 mm;管柱溫度:60℃方法 B
分析型管柱:Stable Bond (Agilent) 1.8 µm;3.0×30 mm;管柱溫度:60℃方法 C
分析型管柱:XBridge (Waters) C18_3.0×30 mm_2.5 µm;管柱溫度:60℃方法 D
分析型管柱:XBridge C18_3.0×30 mm_2.5 µm (Waters);管柱溫度:60℃方法 E
分析型管柱:Sunfire (Waters) 2.5 µm;3.0×30 mm;管柱溫度:60℃方法 F
分析型管柱:XBridge C18 (Waters) 2.5 µm;3.0×30 mm;管柱溫度:60℃。
時間(min) | Vol.-%水(包括0.1% NH4 OH) | Vol.-% ACN | 流速[mL/min] |
0.00 | 97 | 3 | 2.2 |
0.20 | 97 | 3 | 2.2 |
1.20 | 0 | 100 | 2.2 |
1.25 | 0 | 100 | 3 |
1.40 | 0 | 100 | 3 |
時間(min) | Vol.-%水(包括0.1% TFA) | Vol.-% ACN | 流速[mL/min] |
0.00 | 97 | 3 | 2.2 |
0.20 | 97 | 3 | 2.2 |
1.20 | 0 | 100 | 2.2 |
1.25 | 0 | 100 | 3.0 |
1.40 | 0 | 100 | 3.0 |
時間(min) | Vol.-%水(包括0.1% NH4 OH) | Vol.-% ACN | 流速[mL/min] |
0.00 | 95 | 5 | 1.5 |
1.30 | 0 | 100 | 1.5 |
1.50 | 0 | 100 | 1.5 |
1.60 | 95 | 5 | 1.5 |
時間(min) | Vol.-%水(包括0.1% NH4 OH) | Vol.-% ACN | 流速[mL/min] |
0.00 | 95 | 5 | 1.5 |
1.30 | 0 | 100 | 1.5 |
1.50 | 0 | 100 | 1.5 |
1.60 | 95 | 5 | 1.5 |
時間(min) | Vol.-%水(包括0.1% TFA) | Vol.-% ACN | 流速[mL/min] |
0.00 | 97 | 3 | 2.2 |
0.20 | 97 | 3 | 2.2 |
1.20 | 0 | 100 | 2.2 |
1.25 | 0 | 100 | 3.0 |
1.40 | 0 | 100 | 3.0 |
時間(min) | Vol.-%水(包括0.1% NH4 OH) | Vol.-% ACN | 流速[mL/min] |
0.00 | 95 | 5 | 1.5 |
1.30 | 0 | 100 | 1.5 |
1.50 | 0 | 100 | 1.5 |
1.60 | 95 | 5 | 1.5 |
Claims (12)
- 如請求項1之式(I)化合物或其醫藥學上可接受之鹽,其中A為經F、F1-3 -氟-C1 烷基組成之群中的一或兩個成員取代之吡啶基。
- 如請求項1至3中任一項之式(I)化合物或其醫藥學上可接受之鹽,其中E係選自由以下組成之群:視情況經F、F2 HC及F3 C組成之群中的一或兩個成員取代之苯基及吡啶基。
- 一種醫藥組合物,其包含至少一種如請求項1至6中任一項之式I化合物或其醫藥學上可接受之鹽,及一或多種醫藥學上可接受之賦形劑。
- 如請求項1至3及6中一或多項之式(I)化合物或其醫藥學上可接受之鹽,其用作藥物。
- 如請求項1至3及6中任一項之式(I)化合物或其醫藥學上可接受之鹽,其用於治療或預防發炎性氣道疾病或纖維化疾病。
- 如請求項1至3及6中任一項之化合物或其醫藥學上可接受之鹽,其用於治療或預防特發性肺病(IPF)或全身性硬化症(SSc)。
- 一種如請求項1至6中任一項之式(I)化合物或其醫藥學上可接受之鹽的用途,其用於製造供治療或預防發炎性氣道疾病或纖維化疾病之藥物。
- 一種如請求項1至6中任一項之化合物或其醫藥學上可接受之鹽的用途,其用於製造供治療或預防特發性肺病(IPF)或全身性硬化症(SSc)之藥物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19187617 | 2019-07-22 | ||
EP19187617.6 | 2019-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202120492A true TW202120492A (zh) | 2021-06-01 |
Family
ID=67438402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109124572A TW202120492A (zh) | 2019-07-22 | 2020-07-21 | 新穎嗒𠯤 |
Country Status (23)
Country | Link |
---|---|
US (2) | US11485727B2 (zh) |
EP (2) | EP4364805A2 (zh) |
JP (2) | JP2022541065A (zh) |
KR (1) | KR20220038438A (zh) |
CN (1) | CN114206876B (zh) |
AR (1) | AR119453A1 (zh) |
AU (1) | AU2020316643A1 (zh) |
BR (1) | BR112021026887A2 (zh) |
CA (1) | CA3145868A1 (zh) |
CL (1) | CL2022000112A1 (zh) |
CO (1) | CO2022000243A2 (zh) |
CR (1) | CR20220022A (zh) |
DO (1) | DOP2022000008A (zh) |
EC (1) | ECSP22003856A (zh) |
FI (1) | FI4003998T3 (zh) |
IL (1) | IL289788A (zh) |
JO (1) | JOP20220012A1 (zh) |
LT (1) | LT4003998T (zh) |
MX (1) | MX2022000958A (zh) |
PE (1) | PE20220964A1 (zh) |
PT (1) | PT4003998T (zh) |
TW (1) | TW202120492A (zh) |
WO (1) | WO2021013830A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3873472B1 (en) * | 2018-10-29 | 2023-07-12 | Boehringer Ingelheim International GmbH | Novel pyridazines |
US11465982B2 (en) | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
KR102587919B1 (ko) * | 2022-07-22 | 2023-10-11 | 주식회사 넥스트젠바이오사이언스 | 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2671984A1 (en) * | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds |
TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
CN106220572B (zh) | 2011-10-28 | 2019-12-13 | 因西必泰克新有限公司 | 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法 |
SI3269716T1 (sl) | 2013-03-14 | 2020-12-31 | Galapagos N.V. | Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj |
JP6435323B2 (ja) | 2013-06-19 | 2018-12-05 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
GB201503141D0 (en) * | 2015-02-03 | 2015-04-08 | Fosbel Inc | Integral self-supporting refractory checker brick modules for glass furnace regenerator structures, and methods of forming same |
GB201603745D0 (en) * | 2016-03-04 | 2016-04-20 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
WO2017192304A1 (en) * | 2016-05-02 | 2017-11-09 | Inception 1, Inc. | Arylcarboxamides and uses thereof |
KR101798840B1 (ko) * | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
PT3831812T (pt) * | 2018-07-27 | 2023-07-10 | Mitsubishi Tanabe Pharma Corp | Novos derivados de piridina 3,5-dissubstituída e de piridazina 3,5-dissubstituída e utilização farmacêutica dos mesmos |
EP3873472B1 (en) | 2018-10-29 | 2023-07-12 | Boehringer Ingelheim International GmbH | Novel pyridazines |
MX2022000955A (es) | 2019-07-22 | 2022-02-14 | Boehringer Ingelheim Int | Derivados de n-(6-metoxi)pirizadin-3-il) amina, n-metilo como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas. |
US11465982B2 (en) | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
-
2020
- 2020-07-20 US US16/932,882 patent/US11485727B2/en active Active
- 2020-07-21 AU AU2020316643A patent/AU2020316643A1/en active Pending
- 2020-07-21 TW TW109124572A patent/TW202120492A/zh unknown
- 2020-07-21 CN CN202080051863.5A patent/CN114206876B/zh active Active
- 2020-07-21 CA CA3145868A patent/CA3145868A1/en active Pending
- 2020-07-21 MX MX2022000958A patent/MX2022000958A/es unknown
- 2020-07-21 EP EP24157589.3A patent/EP4364805A2/en active Pending
- 2020-07-21 AR ARP200102049A patent/AR119453A1/es unknown
- 2020-07-21 LT LTEPPCT/EP2020/070547T patent/LT4003998T/lt unknown
- 2020-07-21 FI FIEP20743687.4T patent/FI4003998T3/fi active
- 2020-07-21 CR CR20220022A patent/CR20220022A/es unknown
- 2020-07-21 JO JOP/2022/0012A patent/JOP20220012A1/ar unknown
- 2020-07-21 JP JP2022503996A patent/JP2022541065A/ja not_active Ceased
- 2020-07-21 PE PE2022000105A patent/PE20220964A1/es unknown
- 2020-07-21 WO PCT/EP2020/070547 patent/WO2021013830A1/en active Application Filing
- 2020-07-21 KR KR1020227005957A patent/KR20220038438A/ko unknown
- 2020-07-21 PT PT207436874T patent/PT4003998T/pt unknown
- 2020-07-21 BR BR112021026887A patent/BR112021026887A2/pt unknown
- 2020-07-21 EP EP20743687.4A patent/EP4003998B1/en active Active
-
2022
- 2022-01-12 IL IL289788A patent/IL289788A/en unknown
- 2022-01-14 CO CONC2022/0000243A patent/CO2022000243A2/es unknown
- 2022-01-17 EC ECSENADI20223856A patent/ECSP22003856A/es unknown
- 2022-01-17 CL CL2022000112A patent/CL2022000112A1/es unknown
- 2022-01-19 DO DO2022000008A patent/DOP2022000008A/es unknown
- 2022-09-23 US US17/934,625 patent/US20230100516A1/en active Pending
-
2023
- 2023-04-20 JP JP2023069392A patent/JP2023116436A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220038438A (ko) | 2022-03-28 |
JP2022541065A (ja) | 2022-09-21 |
DOP2022000008A (es) | 2022-03-15 |
CA3145868A1 (en) | 2021-01-28 |
EP4364805A2 (en) | 2024-05-08 |
JOP20220012A1 (ar) | 2023-01-30 |
PT4003998T (pt) | 2024-04-26 |
LT4003998T (lt) | 2024-05-10 |
MX2022000958A (es) | 2022-02-14 |
US20230100516A1 (en) | 2023-03-30 |
CO2022000243A2 (es) | 2022-01-17 |
CL2022000112A1 (es) | 2022-10-21 |
WO2021013830A1 (en) | 2021-01-28 |
JP2023116436A (ja) | 2023-08-22 |
IL289788A (en) | 2022-03-01 |
CR20220022A (es) | 2022-03-02 |
BR112021026887A2 (pt) | 2022-04-26 |
PE20220964A1 (es) | 2022-06-10 |
US11485727B2 (en) | 2022-11-01 |
AR119453A1 (es) | 2021-12-22 |
ECSP22003856A (es) | 2022-02-25 |
CN114206876B (zh) | 2024-05-14 |
AU2020316643A1 (en) | 2022-02-17 |
EP4003998A1 (en) | 2022-06-01 |
CN114206876A (zh) | 2022-03-18 |
EP4003998B1 (en) | 2024-03-27 |
FI4003998T3 (fi) | 2024-04-24 |
US20210024495A1 (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202120492A (zh) | 新穎嗒𠯤 | |
CN114127054B (zh) | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 | |
TW202120493A (zh) | 新穎嗒𠯤 | |
TWI818538B (zh) | Lpa受體拮抗劑及其用途 | |
EP3873472B1 (en) | Novel pyridazines | |
AU2020428591B2 (en) | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases | |
CN115087652A (zh) | 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 | |
EA045768B1 (ru) | Производные n-метил, n-(6-(метокси)пиридазин-3-ил)амина в качестве модуляторов аутотаксина (atx) для лечения воспалительных заболеваний дыхательных путей или фиброзных заболеваний | |
CN114845776A (zh) | 可用作ige调节剂的四氢苯并-喹啉磺酰胺衍生物 |